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Business Coalition Development: 
Inlpact on Public Policy and Legislation 
Executive Summary 
My responsibilities as an intern with Pfizer, Inc. 's Michigan Office of State Government 
Relations focused on the development of public policy partnerships with numerous 
organizations including voluntary health associations and senior centers throughout the 
state of Michigan beginning January 1, 2002 and continuing until April 19, 2002. 
Initially, I met ,vith representatives of these groups and others, such as the NAACP and 
AARP, in order to raise the public's awareness of problematic changes to the 
phamlaceutical benefits provided by the state of Michigan to Medicaid 'fee-for-serv'ice' 
recipients and the beneficiaries of other state sponsored health care programs. For this 
purpose, I organized an infoffi1ational meeting at which the attendees \vere informed of 
the adverse changes to Medicaid and the Elder Prescription Insurance Coverage 
programs, followed by a presentation on the innovative Pfizer Share Card, which extends 
pr~scription assistance to seniors who are enrolled in Medicare, lack a prescription dnlg 
benefit and meet specified income guidelines. I subsequently authored regular 
communication updates for the meeting attendees on .tvfedicaid and Medicare related 
issues, as I continued to nieet with additional patient advocacy groups. I \vas charged 
v'lith the responsibility of extending invitations to serve on the Board of Directors for the 
newly incorporated Senior Citizens for Prescription Drug Fairness to representatives of 
the Visiting Physician's Association, NAACP, Epilepsy Foundation, IVrichigan 
Association of Senior Cent~rs and Health Care Partners) and comnlunication was 
facilitated through meetings, conference calls and en1ail. 
As changes to the prior authorization program that adversely affected many Ivfedicaid 
recipients were implemented by the state of rv1ichigan, a campaign strategy to defeat th~ 
initiative was developed, and I served as an information resource both internally and for 
the coalition members and various consulting firms. The campaign evolved into a 
support strategy for alternative legislation providing the state of iVlichigan \vith a ne"v 
revenue source through the extension of Medicaid "best price" rebates to all state run 
health care programs by pharmaceutical manufacturers. The menlDers of the coalition 
consequently becan1e lead contacts in informational breakfasts and luncheons \vith key 
rnembers of the House Appropriations committee. 
Throughout my internship at Pfizer, I have learned that relationships between 
organizations vvith comnlon interests are invaluable~ and by leveraging such synergies, 
public policy can ultill1ately be influenced. The collaborative efforts of organizations 
involved with the campaign against prior authorization are currently being capitalized 
upon, and through this coalition, the changes implemented by the state of Michigan could 
be reversed and/or modified through legislation. My employrnent with Pfizer, Inc. has 
provided exposure to the reality of corporate initiatives with respect to influencing public 
policy through legislation. This experience has allowed my to complete numerous 
challenging tasks while enhancing various skills and abilities. 
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The purpose of this communication is to infonn you of my responsibilities and activities 
to date in my internship with Pfizer, Inc. All infonnation transmitted is considered 
proprietary and confidential. 
Background: 
The State of Michigan is currently experiencing a fiscal crisis, as are many other states. 
In response to the current conditions of the state's finances, certain changes to progran1s 
have been proposed. The Michigan Department of Community Health has proposed a 
much more restricted fonnulary for those recipients of the Elder Prescription Insurance 
Coverage program as well as those Medicaid recipients who are in the "fee for service" 
category. 
Under the current programs, doctors simply prescribe the drug that best suits the patient's 
need. In an effort to resolve a shortfall in the state Medicaid budget, physicians will now 
be required by law to obtain what is referred to as "prior authorization" before prescribing 
any drug not listed on the unrestricted Medicaid fonnulary. In order to obtain prior 
authorization, the physician must place a call to and receive approval from First Health, a 
phannacy benefit manager in Virginia, a process estimated to take ten minutes per 
prescription on average. Due to the extremely limited unrestricted Medicaid fonnulary, 
many drugs now commonly prescribed to patients, such as Celebrex, Lipitor, Geodon, 
Zoloft, and Aricept, are to be placed on prior authorization. This will most likely result in 
the patient being switched from a drug they are currently taking to another, possibly less 
effective treatment with an increased number of side effects. It is also expected that some 
physicians will discontinue the treatment of Medicaid and EPIC recipients due to the 
undue burden that this procedure places on them. 
It is imperative for those individuals who will be affected by these changes in 
phannaceutical availability to be aware of these developments, and the assistance of 
Voluntary Health Associations is being requested in order to ensure that this is carried out 
in the most efficient and effective manner. The best interests of patients and adequate 
patient care can best be protected through collaboration in order to communicate the 
ilnpact of this policy on Michigan's most vulnerable citizens, the less fortunate and the 
elderly. The damage to patient care and physician participation promises to be 
monumental without the response of those who stand to lose the most. 
The Phannaceutical Research and Manufacturer's of America (PhRMA) sued the state of 
Michigan on the grounds that the process by which the prior authorization process was 
implemented was unconstitutional. Several Mental Health advocacy groups have also 
filed suit in this case due to the irreparable hann that this program would cause their 
consti tuen ts. 
Developments: 
On Monday, January 7, 2002, a hearing was held on the motion for preliminary 
injunction brought by PhRMA. The judge ruled in favor of the phalmaceutical and 
mental health plaintiffs and issued an injunction. The Attorney General's motion for stay 
pending appeal was denied, and the language of the order for injunctive relief is currently 
being worked out between the opposing sides. The Attorney General is expected to file 
an emergency appeal in the near future. 
Responsibilities: 
My role in the Michigan Medicaid fonnulary response is that of a liaison between the 
voluntary health organizations of the state and Pfizer. Over the past week, in addition to 
becoming familiar with the fonnulary issue, I have contacted approximately 28 VHA's to 
schedule briefings on this issue. Briefing materials for these meetings have been drafted 
and submitted for approval. 
I began meeting with these groups on Tuesday, January 8, 2002 and have completed 
appointments in the Lansing and Metro-Detroit areas. The response from the associations 
has varied depending on the level that their particular patient bases are affected by the 
fonnulary changes. 
Expectations: 
If the committee deems it appropriate, I will report on a weekly basis throughout the 
duration of the internship and in person when possible. The internship is expected to last 
for sixteen weeks ending on April 19, 2002. 
Committee Members and Contact Information: 
Dr. Harold Black (Chair) Phone: 974-1721 Email: hblack@utk.edu 
Fax: 974-1715 
Dr. David Tandy 
Dr. Bob Cunningham 
Contact Information: 
Hannah Kiser 
Phone: 974-7705 
Fax: 974-7173 
Phone: 974-7050 
Pfizer, Office of State Government Relations 
209 North Walnut, Suite C 
Lansing, MI 48933 
(517) 485-8301 
Email: hannah.kiser@pfizer.com 
hmkiser@utk.edu 
Email: dtandy@utk.edu 
Email: rcunning@utk.edu 
TO: Dr. Harold Black 
Dr. Bob Cunningham 
Dr. David Tandy 
FROM: Hannah Kiser 
DATE: January 21, 2002 
RE: College Scholars Senior Project Report 
Report 
Over the past week, I have contacted forty-one voluntary health agencies, as well as the NAACP 
and AARP, in order to set up briefing appointments on the proposed changes to the Medicaid 
and Elder Prescription Insurance Coverage program [EPIC] formulanes in Michigan. The 
response from the associations has varied; however, most have been very receptive. Some 
agencIes have already taken a proactive approach to ensure quality patient care for their 
constituencies by infoffi1ing government representatives and local media of the eminent adverse 
impact on Medicaid recipients and plan to continue to increase awareness among their 
popUlations. Still others are cognizant of the policy directive, but have not yet taken a position. 
A small minority of organizations has determined that they would be relatively unaffected by the 
possible change in policy and thus, are not planning to address the issue. This communication 
contains a synopsis of the ten group meetings that have taken place thus far in Detroit, Lansing 
and Kalamazoo. 
In meeting with the American Cancer Society, the Director of State Government Relations made 
me aware of Michigan Partners for Patient Advocacy group. This loose coalition of voluntary 
health organizations aims to ensure and protect the quality of patient care in Michigan and has 
kept member groups, of which there are approximately 60, informed of the developments with 
respect to the proposed changes. This group requires consensus in order to take a collective 
stance on any given issue, but has authorized any member organization to react to the policy, as 
they deem appropriate. 
The Mental Health Association has already responded by filing a~ an intervenor in the 
Phannaceutical Research and Manufacturers of America v. Michigan Department of Community 
Health lawsuit. This group would be impacted, arguably more than any other would due to the 
specific nature of mental health drugs. The affidavits filed by two mental health patients indicate 
that any change to the treatment regimen they are now utilizing would be disastrous due to a 
decrease in the quality of life they now experience. The restrictive forn1ulary advocated by the 
Michigan Department of Community Health would equate to catastrophe for these Medicaid 
recipients. 
The Chronic Illness Awareness Coalition, although unable to lobby collectively, is aware of the 
issue at hand, and will communicate to member organizations that infonnation on the forn1ulary 
can be obtained from the Pfizer Office of State Government Relations. The Director of the 
Coalition is directly affected by this policy and provided a copy of their directory for further 
assistance. Although the Department of Community Health has indicated that any drugs not 
listed on the proposed changes list will be available without restriction, she is wary of these 
promises and wants to be kept up to date on all developments. 
Paralyzed Veterans of America are not directly affected by the policy changes due to the fact that 
most of their population has military health benefits. They have, however, proved an invaluable 
resource by recommending other disability groups who have significant Medicaid recipient 
populations. I also participated in a briefing of the Michigan Association of Centers for 
Independent Living in order to make the disability agencies present aware of the situation and 
put them in contact with Pfizer. 
The American Lung Association indicated that some physicians have voiced concern over the 
lack of choice in asthma treatments . They have not been proactive in advocating a position, but 
would be interested in meeting with other voluntary health agencies to discuss the problem and 
assist in suggesting solutions. The Director would also like to be kept abreast of any 
developments. 
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The Huntington's Disease Society was familiar with the Medicaid problem due to their 
participation in the Michigan Partners for Patient Advocacy. Personal experience with the 
disease led the President of the Society to be strongly opposed to the prior authorization process. 
Those suffering from Huntington's disease must have access to different medications as soon as 
possible due to the dynamic nature of this ailment, and the drug that may have worked in the past 
can become ineffective without warning. This group can be expected to be active in combating 
the prior authorization process. 
The Leukemia Society of America was extremely involved in the initial reaction to the proposed 
changes and was very receptive to initiating a grassroots campaign effort. They provided a list 
of their most utilized medications and requested notification of the status of each, as well as, 
referrals to social workers and Gilda's Club, a non-profit home for individuals being treated for 
leukemia who are unable to afford overnight accommodations in the metro-Detroit area. The 
President is also going to brief the contact person on the West side of the state. 
The Epilepsy Foundation of America activated their grassroots network in the initial fight against 
the formulary changes and is willing to do so again. Epilepsy drugs arl similar to those in the 
mental health category in the sense that the treatment is very individual specific. Dilantin, one of 
the best in class anti-epileptic prescription drugs, is on prior authorization, which would without 
a doubt prove detrimental to the treatment of epileptics on Medicaid or the Elder Prescription 
Insurance Coverage program. While seizures can often be treated by other means, these 
alternative prescriptions may not prevent them as well as Dilantin does. This group was 
interested in the possibility of an open forum for agencies opposed to the restrictive formulary 
and offered to help with the organization of such an effort. 
The American Liver Foundation was unaware of the proposed changes to the formulary, and 
while not affected quite as heavily as the other organizations, was not opposed publicizing the 
Issue. The group was encouraged to promote letter writing by those who would be affected. 
The Alzheimer's Association understood the magnitude of the issue and is willing to engage in a 
letter writing campaign. The most well-known prescription medication for Alzheimer's did not 
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require prior authorization; however, Aricept and another treatment are restricted. As was the 
case with nlental health and epileptic medications, these treatments are very patient-specific, and 
restrictions as to necessary treatment would have an extremely negative effect on those suffering 
from this disease. 
In addition, a meeting with the Michigan Association of Senior Centers has taken place and 
further contact and interaction with this pivotal group is anticipated. The Elder Prescription 
Insurance Coverage program is reported to have had minor glitches in coverage, but it is 
expected that prior authorization could completely incapacitate the program's ability to serve 
seniors effectively. 
Summary 
It is apparent that the voluntary health agencies are opposed to the implementation of a restricted 
formulary for Medicaid patients. Many of those whom I met with indicated that they understand 
the importance of fiscal responsibility, but were strongly opposed to the act of "balancing the 
budget on the backs of the most needy citizens." These individuals have more than enough 
difficulty accessing the health care system without the additional burden of this policy. There is 
also evidence that indicates that decreasing prescription coverage leads to increases in 
hospitalization and nursing home costs to the state. [See Print Media] To decrease 
pharmaceutical offerings would upset the delicate equilibrium of Medicaid fee for service 
recipients statewide, which constitutes irreparable harm as the Ingham County district court 
judge so clearly elucidated at the preliminary injunction hearing. 
Developments 
A three-judge panel of the Michigan Court of Appeals has ruled that the stay issued by the 
Ingham County district court is to be reconsidered after a hearing on the merits of the case. 
While this was not the ideal tum of events for the pharmaceutical companies or the patient 
advocacy groups, the outcome could go either way at the appeals level. 
Meanwhile, Pfizer is prepanng the sales force to deal with this issue by formulating the 
necessary forms to obtain prior authorization from the pharmacy benefit manager, should this 
process be implemented. 
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TO: Dr. Harold Black 
Dr. Bob Cunningham 
Dr. David Tandy 
FROM: Hannah Kiser 
DATE: January 28, 2002 
RE: College Scholars Senior Project Report 
Report 
I have continued to contact voluntary health associations and other groups with a vested interest 
in the Michigan Medicaid issue. In addition, the Manager of Pfizer Civic Affairs, an office 
within the Corporate Affairs division located at corporate headquarters, was brought in for the 
purpose of giving me additional training in the method of mobilizing patient advocacy groups. 
Her insight was especially helpful, and I was able to learn several new techniques for engaging 
individuals who manage voluntary health associations. This process, which is more commonly 
referred to as alliance development, is an area of expertise that is currently under development; 
Pfizer has implemented this strategy on a national level over the past few years. Other groups 
such as the Pharmaceutical Research and Manufacturer's of America are also following this 
strategy as means of stimulating organizations to respond to issues which adversely affect them. 
The following is a brief synopsis of the meetings that I have had in the past week. 
The American Heart Association is a part of Michigan Partners for Patient Advocacy. This 
group has experienced major cuts in state program funds and is looking for innovative ways to 
partner with other organizations in order to continue their assistance of those with heart disease 
and other heart-related conditions. They have been in contact with the s.lles force, but have yet 
to enact any programs. They have formed a coalition with the American College of 
Cardiologists on the state level, and this effort resulted in written statement expressing the 
College's displeasure with the proposed formulary changes. Although not affected greatly by the 
change to the Medicaid formulary, the group is concerned due to implementation of these same 
limitations on the EPIC program (Elder Prescription Insurance Coverage). The Heart 
Association seemed open to the possibility of being a more vocal advocate of patients' rights as a 
result of the EPIC changes. 
The legislative director of the Arthritis Foundation informed me of their legislative priority to 
educate legislators as to the threat of arthritis at any age. The organization is currently 
developing a patient advocacy program which is intended to train individuals suffering from 
arthritis to speak with their legislator with the hopes of increasing funding for arthritis treatment 
and cure research. The director intends to attend the forum for voluntary health associations and 
senior centers, and she was in agreement about imminent adverse impact on patient care in the 
state. This group partnered with the Michigan Department of Community Health on a 
publication entitled the "Michigan Arthritis Action Plan," but the extent to which they are 
involved with the Department has yet to be determined. 
American Autoimmune Related Diseases is an organization with a federally focused agenda. 
Recently, they were influential in advocating a $420 million dollar legislative program within the 
Children's Health Act, which is designed to further Autoimmune disease research. Federal 
issues of this magnitude coupled with the rather small staff make it difficult for the group to be 
heavily involved in state issues. The organization has however, signed onto a statement 
opposing the proposed changes to the Medicaid and EPIC formularies, and they are also open to 
informing their popUlation of the policy through direct n1ail. The director will be unable to 
attend the meeting, but would be interested in hearing the outcome. 
In addition to these meetings, I have assisted with the preparation of a PowerPoint presentation 
summarizing the issues Pfizer is facing in Michigan for presentation to a national audience. [See 
attached.] This presentation explains the process of prior authorization, as well as, the effect that 
such a policy could have on the company's profit margin. The implications of this policy are not 
limited to the state of Michigan, as other states could follow this directive if implemented, which 
would result in a blow to the research and development industry. Without the input of those who 
stand to lose the most, any attempts made to defeat this policy by a pharmaceutical firm will be 
viewed as self-serving. Therefore, the input of all affected by this policy is imperative to a 
successful rebuttal of the proposed changes, and those in political office must be aware of the 
political magnitude of this decision. 
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Summary 
The groups I have met with have all been in agreement that the proposed policy has a negative 
impact on patient care. Most of the groups are very concerned and have already been involved in 
a public response and are interested in a collaborative effort to prevent this from going into 
effect. It has been a learning experience to work with so many different individuals with such 
varied degrees of expertise and unique approaches. The job of developing relationships with 
such interesting people has been exciting, and I look forward to continuing to meet and interact 
with a variety of personalities marked by unique senses of purpose. 
Developments 
Pfizer also announced the Pfizer Share Card which allows Medicare recipients to purchase Pfizer 
prescriptions at the cost of $15 per 30 day supply upon meeting minimal income qualifications. 
The program has no limits and is targeted at the 7 million Medicare recipients who currently 
have no prescription coverage. The voluntary health associations are pleased to hear that Pfizer 
is taking a stand and providing much needed assistance to this group of people. 
As suggested by the senior campaign consultant, a meeting of all voluntary health associations 
who wish to participate has been scheduled for February 5, 2002. This meeting will allow those 
groups who have not yet been briefed regarding this issue to be brought up to speed, as well as 
refresh those organizations that are aware of the current situation. The goal of the meeting is to 
promote a collaborative effort between these organizations so that legislators and other public 
officials will become aware of the negative impact of this restrictive policy. 
The changes to the Medicaid pharmaceutical policy are scheduled to take effect on February 1, 
2002; however, there are indications that the pharmacy benefit manager may be unprepared to 
begin the provision of the services necessary to run the program. The Pharmaceutical Research 
and Manufacturer's lawsuit is still to be heard at the Court of Appeals, at which time the 
constitutionality of the policy will be determined. 
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TO: Dr. Harold Black 
Dr. Bob Cunningham 
Dr. David Tandy 
FROM: Hannah Kiser 
DATE: February 4, 2002 
RE: College Scholars Senior Project Report 
Report 
Over the past week, I have primarily focused on preparing for the meeting of voluntary 
health associations and senior centers, which will take place on Tuesday, February 5, 
2002. The goal of this nleeting is to brief the associations on the Pfizer Share Card and 
inform them of the changes to the Medicaid formulary . We hope to then gather feedback 
on ways that the groups can collaborate in order to change the proposed policy through 
grassroots advocacy. At the present time, we expect approximately 15 voluntary health 
associations to be represented, in addition to a number of senior center representatives. 
In addition, I also met with the president of the Immune Deficiency Foundation of 
Michigan. Their population has a large number of Medicaid recipients, and they were 
very concerned with the changes, which were to be effective on February 1, 2002. The 
group has an interesting history of grassroots advocacy on a national level, as they 
recently battled Disney on the release of a movie entitled "Bubble Boy," which depicted 
a child with immune deficiency disorder in what was considered a romantic comedy. 
The group, although unsuccessful in preventing the release of the film, strove to educate 
the public about the gravity of the disease. While they have not yet been involved with 
the issue of the Medicaid formulary and are required to submit such proposals to their 
national affiliate prior to taking action, they were extremely open to weighing in on the 
issue due to the negative impact on their constituency. 
One of the voluntary health association leaders with whom I had previously met 
contacted me early on the morning of February 1, 2002 to inform me that she had 
received a letter notifying her of the changes to Medicaid offerings on January 31. The 
letter from the Director of Medicaid was dated "January 2002" and vaguely indicated that 
there would be changes to Medicaid pharmaceutical benefits in order to ensure the 
ongoing provision of coverage by the state. She indicated that had we not met to discuss 
the issue, she would not have realized the extent of the changes in pharmaceutical 
availability or the new procedural requirements. She voiced grave concern for Medicaid 
recipients, of which there are estimated to be 350,000 to 400,000 in the Medicaid "fee-
for-service" population, due to the vague nature and poor timing of the letter. I was able 
to provide her with contact information for her state legislators, as well as the chairs of 
the Community Health subcommittee chairs in the Senate and House, so that she could 
voice her displeasure with the policy changes and the unacceptable manner in which the 
recipients were notified. She was very clear in articulating her concern that this policy 
change could have life and death implications for recipients in her organization's 
population. 
I am looking forward to the meeting of the voluntary health associations, because there 
has not yet been an organized open forum for the communication of specific concerns 
about this policy initiative. Due to the circumvention of the legislative process in the 
implementation of this policy, public response on the issue was never considered, and the 
changes were never submitted to the legislature as a whole. The individuals planning to 
attend include mental health advocates, AIDS representatives, as well as representatives 
organizations such as the Epilepsy Foundation, who represent segments of the population 
impacted significantly by changes in the availability of prescriptive treatments. 
Summary 
Up to this point, I have contacted approximately sixty voluntary health organizations in 
order to notify them of the changes to the formulary. Some have already weighed in on 
this issue, and those I have met with have voiced serious concerns regarding the effect 
this change will most likely have on the Medicaid and other affected popUlations. The 
inefficiency of the Medicaid agency has been alarming, and when questioned Friday on 
the schedule of implementation for the formulary changes, one Medicaid employee 
confessed, "It's just one big mess." It is unfortunate that the state has chosen to 
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haphazardly enact changes at the expense of Medicaid recipients, and it seems that the 
Medicaid agency is only beginning to comprehend the "mess" that has been created. 
Developments 
The formulary was scheduled to go into effect on Friday, February 1, but it seems that the 
Department of Community Health is not prepared to implement the proposed changes. In 
print media, one spokesperson for the Department of Community Health reported that the 
formulary changes would be effective as of February 1, but would not be enforced "for a 
few weeks". In fact, changes to the list of drugs requiring prior authorization were 
evident on the morning of February 1, when Lipitor and possibly others were 
unexpectedly changed to unrestricted status. It is apparent that the policy changes were 
not thoughtfully considered, and now that the time has come to in1plement the proposal, 
neither the State nor the pharmacy benefit manager is prepared to enforce the changes. 
There is also a meeting scheduled for Monday, February 4, which will allow consumer 
advocates and providers to voice input on the Governor's expansion of Medicaid 
coverage to an additional 200,000 recipients through a broad waiver. The groups will be 
asked to comment on the eligibility, benefits and budgeting aspects of the expansion 
proposal. Several of the advocates with whom I have networked are planning to attend 
because they are concerned that the expansion will be employed at the expense of the 
existing beneficiaries, namely their constituents. 
Also included with this report are materials prepared for the meeting of voluntary health 
organizations and senior centers to be held on Tuesday, February 5, 2002 such as 
Medicaid Health Alert and form letters directed toward legislative officials. 
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[Date] 
The Honorable [Full Name] 
State Representative 
State Capitol 
P.O. Box 30014 
Lansing, MI 48909-7514 
Dear Representative [Last Name]: 
I am writing to inform you of my objections to the proposed changes in the Elder Prescription 
Insurance Coverage program. This program was established to "enhance access" to 
pharmaceutical medications for low-income senior citizens of the state of Michigan. The 
proposed changes to the program will not only restrict access to prescription medication, but 
could also prompt physicians to discontinue the treatment of EPIC recipients due to the undue 
bureaucratic burden placed on them through the prior authorization requirements and restricted 
formulary. 
The physician should be the one to determine the best treatment for the patient if adequate 
patient care is to be achieved, and heightened prior authorization requirements will not only 
circumvent physician expertise but also simultaneously erode patient care. A healthcare 
operative in Virginia is not properly equipped to determine the appropriate prescription for the 
Michigan citizen. 
The EPIC program is in place for the purpose of helping the senior citizens of Michigan with life 
sustaining prescription costs, and I assert that if seniors are forced to discontinue the use of 
medications which have currently stabilized their conditions and switch to other forms of 
treatment which may be less effective and cause additional side effects, the result will be 
disastrous. This group of citizens has contributed to the state of Michigan over the years, and it 
is an outrage to decrease the prescription benefits provided to these individuals. 
* [I am currently taking , which is expected to be placed on prior authorization if 
the changes to EPIC are implemented.] I am very concerned for my own well being and the well 
being of the seniors of Michigan; I urge you to do whatever is necessary to ensure that these 
changes are reconsidered in a manner that would be advantageous for the seniors of Michigan. 
Sincerely, 
[Your Name & Address] 
[Date] 
The Honorable [Full Name] 
State Representative 
State Capitol 
P.O. Box 30014 
Lansing. MI 48909-7514 
Dear Representative [Last Name]: 
I am writing to express my strong opposItIon to the implementation of increased prior 
authorization procedures in Michigan's Medicaid and Elder Prescription Insurance Coverage 
(EPIC) programs. It is wrong to remedy budget shortfalls by making appropriate treatments less 
accessible to Michigan's most vulnerable citizens, the less fortunate and the elderly. 
Furthermore, this process strips the physician of the ability to prescribe the most appropriate 
medication by limiting access through a restricted formulary or alternately, requiring approval 
from an out of state pharmacy benefit manager with no knowledge of the patient's needs. 
The Michigan Department of Community Health's mission statement reads as follows: 
1. to promote access to the broadest possible range of quality services and supports 
2. to take steps to prevent disease, promote wellness and improve the quality of life 
3. to strive for the delivery of those services and supports in a fiscally prudent manner 
Clearly, the limitation of pharmaceutical availability through prior authorization requirements 
and a restricted formulary directly oppose the goal of promoting access to the broadest range of 
quality services and supports, while forcing patients currently stabilized on medications to alter 
their treatment contradicts the promotion of wellness and the improvement of the quality of life. 
It is therefore impossible to deliver the aforementioned services and supports, defeating the goal 
of doing so in a fiscally prudent manner. Increases in prior authorization requirements and 
restricted formularies are clearly contradictory to the mission of the Michigan Department of 
Community Health. 
It is the duty of elected representatives to uphold the principles of equality and democracy by 
ensuring that the well being of their constituency is protected. The proposed changes to the 
Medicaid/EPIC formulary violate the very purpose of the Michigan Department of Community 
Health and in doing so, endanger the well being of the MedicaidlEPIC recipients. It is my hope 
that you will hold the Michigan Department of Community Health to its mission by ensuring that 
the proposed changes are reconsidered, and thereby protect the well being of the citizens of the 
state of Michigan. 
Sincerely, 
[Your Name & Address] 
[Date] 
The Honorable [Full Name] 
State Senator 
State Capitol 
P.O. Box 30036 
Lansing, MI 48909-7536 
Dear Senator [Last Name]: 
I am writing to inform you of my objections to the proposed changes in the Elder Prescription 
Insurance Coverage program. This program was established to "enhance access" to 
pharmaceutical medications for low-income senior citizens of the state of Michigan. The 
proposed changes to the program will not only restrict access to prescription medication, but 
could also prompt physicians to discontinue the treatment of EPIC recipients due to the undue 
bureaucratic burden placed on them through the prior authorization requirements and restricted 
formulary. 
The physician should be the one to determine the best treatment for the patient if adequate 
patient care is to be achieved, and heightened prior authorization requirements will not only 
circumvent physician expertise but also simultaneously erode patient care. A healthcare 
operative in Virginia is not properly equipped to determine the appropriate prescription for the 
Michigan citizen. 
The EPIC program is in place for the purpose of helping the senior citizens of Michigan with life 
sustaining prescription costs, and I assert that if seniors are forced to discontinue the use of 
medications which have currently stabilized their conditions and switch to other forms of 
treatment which may be less effective and cause additional side effects, the result will be 
disastrous. This group of citizens has contributed to the state of Michigan over the years, and it 
is an outrage to decrease the prescription benefits provided to these individuals. 
*[1 am currently taking , which is expected to be placed on prior authorization if 
the changes to EPIC are implemented.] I am very concerned for my own well being and the well 
being of the seniors of Michigan; I urge you to do whatever is necessary to ensure that these 
changes are reconsidered in a manner that would be advantageous for the seniors of Michigan. 
Sincerely, 
[Your Name & Address] 
[Date] 
The Honorable [Full Name] 
State Senator 
State Capitol 
P.O. Box 30036 
Lansing. MI 48909-7536 
Dear Senator [Last Name]: 
I am writing to express my strong opposItIon to the implementation of increased prior 
authorization procedures in Michigan's Medicaid and Elder Prescription Insurance Coverage 
(EPIC) programs. It is wrong to remedy budget shortfalls by making appropriate treatments less 
accessible to Michigan's most vulnerable citizens, the less fortunate and the elderly. 
Furthermore, this process strips the physician of the ability to prescribe the most appropriate 
medication by limiting access through a restricted formulary or alternately, requiring approval 
from an out of state pharmacy benefit manager with no knowledge of the patient's needs. 
The Michigan Department of Community Health's mission statement reads as follows: 
1. to promote access to the broadest possible range of quality services and supports 
2. to take steps to prevent disease, promote wellness and improve the quality of life 
3. to strive for the delivery of those services and supports in a fiscally prudent manner 
Clearly, the limitation of pharmaceutical availability through prior authorization requirements 
and a restricted formulary directly oppose the goal of promoting access to the broadest range of 
quality services and supports, while forcing patients currently stabilized on medications to alter 
their treatment contradicts the promotion of wellness and the improvement of the quality of life. 
It is therefore impossible to deliver the aforementioned services and supports, defeating the goal 
of doing so in a fiscally prudent manner. Increases in prior authorization requirements and 
restricted formularies are clearly contradictory to the mission of the Michigan Department of 
Community Health. 
It is the duty of elected representatives to uphold the principles of equality and democracy by 
ensuring that the well being of their constituency is protected. The proposed changes to the 
MedicaidlEPIC formulary violate the very purpose of the Michigan Department of Community 
Health and in doing so, endanger the well being of the MedicaidlEPIC recipients. It is my hope 
that you will hold the Michigan Department of Community Health to its mission by ensuring that 
the proposed changes are reconsidered, and thereby protect the well being of the citizens of the 
state of Michigan. 
Sincerely, 
[Your Name & Address] 
OPTIONAL PARAGRAPHS 
According to the Michigan Constitution, public health and the general welfare of the people of the state of 
Michigan are matters of primary public concern. As a concerned citizen of this state, it is my finn belief 
that the practice of denying appropriate care to Medicaid recipients through pharmaceutical fonnulary 
limitations and prior authorization requirements is unacceptable. It is clear that the creators of the 
proposal for Medicaid reform have chosen to balance a budget at the expense of the individuals in the 
most critical need of proper medical attention, while the importance of public good has been lost and the 
focus has been shifted instead to the bottom line. While fiscal responsibility is of the utmost importance, 
this priority should not preempt the provision for those individuals least able to access proper medical 
attention as is so adequately stated by the Constitution of this state. The shortfall in the Medicaid budget 
should certainly be addressed and remedied, but not at the expense of Michigan's most vulnerable 
citizens. 
While a committee may be able to determine the least costly drugs in each class, the "best in class" title 
chosen for such Medicaid prescription medication is certainly far from accurate. The fonnulary drugs 
were not chosen with regard to effectiveness or efficiency, two of the criteria the Michigan Department of 
Community Health purports to adhere to in their health care delivery policy. Regardless of the extensity 
of the research behind such classifications, it cannot replace a physician's expertise. When given a choice 
between an unbiased physician analysis and a restricted prescription detennined by a committee that the 
patient has never met, the physician's analysis would undoubtedly be preferred. In fact, if the committee 
members responsible for the "best in class" drug list were subject to this limited formulary, they might be 
more likely to expand the offerings provided to Medicaid beneficiaries. The poor and elderly should not 
suffer merely because it is the most convenient way to solve budget shortfalls. 
The quality of patient care for Medicaid recipients is in jeopardy if the proposed changes to the Medicaid 
phannaceutical offerings are not more closely examined and revised. The list of drugs requiring prior 
authorization is copious, and one can only imagine the effect of switching a patient from an effective, 
slightly more expensive medication to a less expensive, less effective prescription with additional side 
effects. For those taking a number of prescription medications, this process could be catastrophic and the 
damage irreparable. The trauma for Medicaid recipients could be completely avoided, however, if the 
Michigan Department of Community Health remained cognizant of the agency's goal, which aims to 
"design and implement a service delivery system ... that is accessible, efficient, effective and innovative." 
A restricted fonnulary and severely diminished access to phannaceuticals through prior authorization 
meets neither of these criteria and in fact, is contradictory to the aforementioned goal of the agency. 
Patient care should be the utmost priority for the Department of Community Health as the agency so aptly 
states, however, the current proposal is lacking and should therefore be revised. 
Mental health may be one of the most sensitive aspects of managed health care. Due to the fact that 
numerous attempts to find a successful treatment are often necessary and compliance with the successful 
regimen is essential, the current modifications to the Medicaid formulary will likely result in grave 
damage to the mental health care of Medicaid and EPIC recipients. Not only will the doctors be limited 
to a restricted number of approved prescription options, but the will also be subject to prior authorization 
requirements should they deem a restricted phannaceutical the most appropriate choice for their patient. 
These patients' needs are no less important than those who can afford to pay top dollar for mental health 
care, and these individuals should not be forced to carry the burden of balancing a Medicaid budget 
shortfall. Rather, the Michigan Department of Community Health should reconstruct a plan more 
sensitive to the needs of some of Michigan's most vulnerable and at-risk citizens. 
TO: Dr. Harold Black 
Dr. Bob Cunningham 
Dr. David Tandy 
FROM: Hannah Kiser 
DATE: February 11,2002 
RE: College Scholars Senior Project Report 
Report 
On Tuesday, February 5, 2002, representatives from fifteen voluntary health associations and thirty 
senior centers came together at the first coalition meeting to discuss the changes to the Michigan 
Medicaid and EPIC formularies and the effect these changes will have on their respective 
populations. The meeting opened with frank input from the meeting participants regarding the 
positive aspects, as well as the shortcomings, of the current Medicaid and EPIC programs. Many of 
the individuals employed at the senior centers deal with EPIC patients on a daily basis as they assist 
enrollees with the application procedure. The voluntary health association representatives, which 
included an HIV/AIDS advocate, Epilepsy Foundation staff, Lupus Foundation Director and home 
care registered nurses, among others, are in contact with recipients of the Medicaid "fee-for-
service" recipients and are consequently able to assess the likely impact of changes to benefits on 
this constituency. The changes to the EPIC program evoked frustration and even anger from a 
number of senior center representatives who have enrolled individuals believing that it would 
provide access to the necessary pharmaceuticals for seniors who had no other prescription coverage. 
These senior center representatives voiced concern that those seniors who are currently stabilized on 
treatments, which will require prior authorization under the changes to be enforced on February 11, 
2002, will be adversely affected by the policy. 
After questions were fielded on the Medicaid issue, I gave a presentation on the Pfizer Share Card 
program. [See attached.] The group was extremely interested in this new approach to senior 
assistance and seemed excited to be able to offer such a reachable option to those seniors who 
qualify. In total, over 3200 requests for Share Card brochures were turned in, indicating the 
overwhelmingly positive response to this innovative initiative. Over lunch, meeting attendees 
commented that other pharmaceutical companies should consider implementing comparable 
programs. Several senior centers requested that a representative of our staff present the program to 
that a representative of our staff present the program to their respective senior centers. The meeting 
concluded by answering any remaining questions from the audience. 
I met with the governmental relations representative of the AARP to discuss the Medicaid issue, 
and this meeting turned out to be surprisingly advantageous. The organization generally advocates 
preferred prescription medication lists and fonnularies, believing that such practices place 
"downward pressure" on phannaceutical prices. While the representative did acknowledge that 
prescription medicine can lower hospital and nursing home care costs, they asserted that policies 
encouraging the use of generics are of benefit due to their belief that it causes a decrease in the price 
of brand name drugs. When it was pointed out that Pfizer does not dispute the use of generic 
medications, but brand name drugs are sometimes more appropriate treatments, they did not 
disagree but were not swayed in their mindset. 
Their representative also reported that they were planning to file an amicus curiae brief on behalf of 
the state of Michigan on this particular issue. Anticipating that seniors would perceive AARP as 
being in favor of phannaceutical restrictions, he also indicated that the group was planning to 
produce a brochure directing seniors to their phannaceutical company to inquire as to why the 
company had not provided the requested rebates to the state. He also suggested that our corporate 
headquarters contact their national office, so that the state offices would have the authority to refer 
inquiries to the Share Card 800 number, despite the supportive press release of the national office 
on the Share Card. This infonnation was of note to Pfizer, NY, and subsequently another vocal 
senior group has been contacted for their input on the changes to the Medicaid and EPIC program. 
After these developments, I have followed up with the groups present at the meeting, while also 
trying to schedule appointments with those who were not able to attend. The groups present have 
been very complimentary and are excited about the Share Card. It will be more of a challenge to 
see that they follow through with contacting their legislative officials on the subject of the changes 
to Medicaid and EPIC. A follow-up email was sent to the attendees, while contact is also being 
made by phone as well. 
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Summary 
The meeting of the health associations and senior centers was a success in that it provided a forum 
for groups to come together and discuss the current policy, as well as, comment on the negative 
aspects of the changes. Representatives have indicated to me that it was beneficial for them to 
interact with their contemporaries and discuss possible solutions to current situations. Meeting with 
AARP provided me with valuable information that allowed Pfizer to take a proactive approach to 
their alliance with the state on this issue. 
Developments 
The sales force has stal1ed to relay horror stories from physician's offices frustrated by the increase 
in red tape. One office reported being put on hold for over twenty minutes in an attempt to get prior 
authorization for a single prescription, only to be denied and then directed to the emergency 
number, where the staff member was put on hold for another fifteen minutes. After explaining the 
medical necessity of the prescription due to the patient's aggressive behavior, the request was 
finally approved. This is just one instance that has been reported, and it is anticipated that this will 
be the rule rather than the exception. When our office asked for a copy of the Medicaid and EPIC 
prior authorization forms on Wednesday, February 6, 2002, the pharmacy benefit manager 
representatives were less than equipped to answer questions, but finally provided our office with the 
necessary documents. Meanwhile, members of the sales force are trying to come up with ways to 
assist physicians and their staffs in the onerous process of receiving prior authorization. 
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TO: Dr. Harold Black 
Dr. Bob Cunningham 
Dr. David Tandy 
FROM: Hannah Kiser 
RE: College Scholar Senior Project Report 
DATE: February 18, 2002 
Report 
Following up with the individuals who attended the February 5 meeting has been an 
involved process. In addition to informing them that we will be able to send the Pfizer 
Share Card enrollment kit, I have also been inquiring as to whether or not they have been 
in contact with any legislative officials with respect to the changes to the Michigan 
Medicaid formulary. Most are waiting to contact their officials until they have personal 
interaction with an individual who has difficulty accessing their prescription medication 
due to the prior authorization policy, however, the Department of Community Health 
recently issued a letter stating that February 1-8 was a designated "testing period" and 
that the prior authorization system would not be implemented until "at least February 
25." The Department then plans to phase in drug classes on a specified schedule, the first 
to be affected being the antianxiety, antihistamines, glucocorticoids and macrolides. 
I have updated those who attended the coalition meeting of the Department's 
announcements, as well as the position of AARP on this issue. The response to the 
AARP amicus brief has been surprising. One senior center representative who is also in 
charge of the local AARP chapter was shocked at the organization's position and 
contacted the AARP State Government Affairs Representative, with whom I had 
previously met to discuss the issue of the changes to Medicaid prescription benefit. She 
intends to advise neighboring AARP chapters of the position taken by the state office and 
was incensed that there was no chance for local chapters to offer input. 
The Visiting Physician's Association has begun compiling data on the amount time 
devoted by the staff to prior authorization requests and the outcome of such requests. 
Their representative reported that the care coordinators, whose job it is to submit prior 
authorization requests, are extremely frustrated and would have the data together by the 
end of the week to be sent electronically. 
The Leukemia and Lymphoma Society Patient Services Representative who attended the 
Michigan Health Alert coalition meeting indicated that the Medicaid issue was of 
importance to their population, however, the state branches are not permitted to act 
without the approval of the national office on any given issue. She referred me to the 
organization's Government Relations spokepersons in Washington, D.C., and through 
Pfizer's Civic Affairs office in New York contact was made. The Government Relations 
spokesperson was extremely pleased to hear that members on the state level were 
interested in patient advocacy initiatives and approved mobilization of the patient 
advocacy base in Michigan. 
In addition, I have drafted language for the contracts to be submitted to the consulting 
firms whose services are to be employed in the campaign against prior authorization. 
These contracts will include deliverables and payment schedules, as well as a complete 
listing of expectations specific to each firm. 
On behalf of Pfizer, Inc., I attended the Michigan League of Conservation Voters 
Legislative Awards Breakfast, where four state legislators were honored for their 
exemplary commitment to environmental issues, such as proposing a process to develop a 
set of land use planning goals to guide state investments and effecting strategies to 
contain invasive species and mitigate their impact on the Great Lakes. One of the 
representatives recognized represents the district in which the Pfizer Global Research and 
Development facility is located and has explored previous partnerships between Pfizer 
and the HIV / AIDS Alliance located there. 
Modifications to the Michigan Medicaid Changes presentation were also necessary to 
prepare for presentation to the sales force. The docun1ents necessary to the understanding 
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of this complex issues are to be explained if full detail, so the field force representatives 
can assist physicians in the prior authorization process. 
Developments 
The Michigan Department of Community Health released a letter on February 11, 2002, 
which detailed the Department's plans to postpone the implementation of the prior 
authorization system. While the communication included a schedule of proposed 
implementation dates, the letter stated the system would not be enacted until "at least 
February 25, 2002." [See attached.] 
The Seniors Coalition, a vocal national organization of senior citizens, is planning to file 
and amicus brief siding with the Phannaceutical Research and Manufacturers of America 
in the lawsuit against the Michigan Department of Community Health. 
Summary 
While AARP's decision to side with the state of Michigan on the prior authorization issue 
was certainly surprising and not of assistance to our efforts, the anticipated response by 
the Seniors Coalition will be an asset to the campaign against prior authorization. In fact 
some of the local AARP chapters have been contacting the state office with inquiries as 
to why this particular position was taken. In addition, they are not pleased that the local 
chapter constituencies were neither consulted nor infonned of this decision. 
The phase-in announced by the Department is indicative of the pharmacy benefit 
manager's inability to accommodate the prior authorization demand of the physicians and 
their staffs and the Department's haphazard approach to implementing the program. By 
phasing in classes of drugs, the Department hopes to be able to employ the program more 
successfully than was done in the disastrous "testing period." Meanwhile, the various 
aspects of the campaign against prior authorization are moving forward. 
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STATE OF U'C;HIGAN 
DEPARTMENT OF COMMUNITY HEALTH 
Fcbru.ary 11.2002 
Dear ProviderlPrescribcr: 
LliWI6 CASS 8lJH.O'Mca 
LANSING. I.I'C ... I(I.\,. .. ,:1 
JAMU /c. >U.vIiMAN. JR .• Oil..,,'" 
On February 1. 2002. the Michigan DepartmCllt of Community Health beaan the implcrru::ot.ltion 
of the expanded prior authorization pl'OgrBm for phannaccutical.s without denial of dzvp that 
will require prior AuthorizatiOn.. The week of February J - 8 was designated as a testing period 
and a time for prescribers to fax in or wi in prior auilioriution n:quests. This pre-
imple.mentltion prior authorization period will be eXlcmdcd to Fcbn.wy 24. 2002. Thus. prior 
authorization will not be required to fin prescriptions unlil at least February 25. 2002. On 
Fcbcuary 25. 2002, the depautmcnt will begin phasiog in specific; drYg classes Rquiring prior 
authoriution to dispense. The phase in will continue through March 18, 2002. The cbsses of 
drugs ilI1d dates of implementation ofthc prior authori1.ation r~quircment are enclos~d. 
Prior authorization may be requested for any of the drugs that will require prior authorization at 
any time during this philse in by calting the First Healrb Services Corporation's [FHSq Clinical 
Call Ccn~ at 1-877-864-9014 or by filXing yow requ~t to FHSC at 1-888-603-7696 or 1-800-
2S()..69S0. A fux. form is enclosed and may be duplicated for your usc. The fonn identifies the: 
information \hat wiU be required to grant prior authorilation. 
FHSC will prioritize prior authorization requests according to the phase in date for the 
thernpcutic class of drug requested. Requests for drugs in the: February 25. 2002 phase in will be 
addressed prior to requests for drugs from later phase in datl.:s. 
Also cncloscd is a list of drugs th3t do not ~quirc prior authorization in most cases. W. urge 
providers to prescribe from this list and only call for prior authorization when clinically 
neccssmy . 
Please note, drugs that required prior authorization before Fcbruary 1. 2002 will continue to 
require prior allthorization, and all related edits will remClin in force. The dcparuncnt docs not 
caVa' refills until 7S percent of1hc prcvio\lj prescription has bten used. 
For general questions regarding this prol:ram. provideu should contact the FHSe Tcc:hnical Call 
Center at 1-877-624-5204. 
[. 02-09 
L 02·09 • AlI.1chmC:Dt 
MichiglD Department of Community Health 
Timeline For The rapeutic Class Phase ]n of the Implementation of tbe EJpanded Prior Authorization 
February-1\larch 2002 
February 25, 2002 
AnrianxicTy 
_ Antihistamines 
G1ucocorticoids 
Macrolides 
' :"" 
March 4, 2002 
eN S Stimulants 
Oni HypogJycemics 
1st Gen. Cephalosporms 
2nd Gen. Cephalosporins 
Angiotensin Receptors 
Beta Blockc~ 
NSAlD3 
Atypical Antipsychotic!; 
Typical Aftlipsychotics 
~1arch 11,2002 J\'farch 18,2002 
Alzhcimers 
ACE Inhibitors 
Anti-fwlgals 
Coronar}' Vasodilators 
Iruulins 
Anti-Hyperlipidemic Agents 
Narcotics 
Platelet Inhlbitol") 
Quinolones 
RespiratOlY Beta Adrenergic Inhalers 
Sedative Hypnotics Non-Balbituates 
- Steroids, Nasal 
Steroids, T opica1 
Topical Nitroglycerin 
! ! 
PPIs 
Anti-Depressants 
Calcium Channel Blockcrs 
Osteoporosis Agents 
BipoJar Agents 
Antivirals 
H2 Antagon~ts 
TO: Dr. Harold Black 
Dr. Bob Cunningham 
Dr. David Tandy 
FROM: Hannah Kiser 
DATE: February 25, 2002 
RE: College Scholars Senior Project Report 
Report 
Additional partnerships with voluntary health associations have been fostered over the 
past week. My initial contact with the Juvenile Diabetes Research Foundation 
International (JDRFI) led me to believe that this organization would not be of much 
assistance to the campaign against prior authorization; however, when I met with them, 
they were extremely interested in the issue and its ramifications. The advocacy of this 
organization tends to be on the national level, as their chief goal is to increase research 
funds to find the cure of juvenile (Type I) diabetes. Their representative works closely 
with other non profit groups because of personal health experience and referred me to a 
small, but active mental health advocacy group, which she thought would be interested in 
this issue and might possibly weigh in. JDRFI asked to be kept up to date on the issue 
and was open to the possibility of making a position statement and involvement in a letter 
writing campaign. 
Through a joint meeting with the National Family Caregivers Association, the Well 
Spouse Foundation, House Call Physicians and the Maria Madeline Project, I was made 
aware of the priorities of these groups as they relate to home bound individuals. The 
Well Spouse Foundation primarily focuses on providing emotional support to the spouses 
of the disabled, while National Family Caregivers is similar in these interests and is 
supported by Pfizer on the national level. House Call Physicians works hand in hand 
with the Academy of Home Care Physicians, and provides service to Medicare recipients. 
The Maria Madeline Project is an organization that has developed intergenerational 
software for use at senior centers, nursing homes and retirement facilities. These groups, 
with the exception of the Maria Madeline Project, are active members of the Chronic 
Illness Coalition, and are very interested in the possibility of phannaceutical companies 
taking a nl0re proactive role with this group. All the groups expressed concern over the 
prior authorization issue and were open to relaying information on the failure of the 
system upon its implementation. In fact, one of the Health Care Partners nurses at the 
meeting indicated they had already experienced adverse patient care effects with their 
clients during what was considered the "testing period". The groups were pleased to hear 
about the Share Card and are planning to promote it to their populations. 
Each group also had suggestions for possible partnerships with Pfizer. The Maria 
Madeline Project is interested in Pfizer moderating a chat room on their interactive 
website for seniors (www.mariamadeline.com). I indicated that I would make the 
appropriate corporate contacts aware of this idea, and that upon the submission of a 
proposal including budgetary figures, the grant review committee would consider this 
possibility. The site is currently providing medical advice through the Health Care 
Partners group, as well as spiritual reflection and cooking expertise for seniors. 
Partnerships with Ford Motor Company and the UAW have made the software program 
available in two of their retirement centers in Michigan and Texas with plans to expand 
to thirty-one national centers. 
House Call Physicians expressed interest in a Pfizer representative presenting on the 
Share Card at the annual conference of the American Academy of Home Care Physicians 
and the American Geriatrics Committee in May, while the President of National Family 
Caregivers and the Chronic Illness Coalition would like Pfizer to present on the Share 
Card and prior authorization issue at one of the bimonthly meetings and their semiannual 
forum. In addition, they are interested in sponsoring a special event at which celebrity 
physician and founder of Gesundheit Institute, Patch Adams would be the keynote 
speaker. 
The National Organization for Rare Disorders has been, up to this point, a solely national 
organization. The Michigan state branch, which is presently in the development stage, 
will serve individuals diagnosed with any of 6,000 rare disorders in tandem with the 
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national organization on state level issues. The Michigan state branch is to serve as a 
model for all other state branches and is now beginning to identify and consider state 
issues. Their representative was opposed to the prior authorization policy from both a 
personal and organizational standpoint. She is planning to submit the issue to the 
national office to receive authorization to weigh in, but regardless will personally write to 
indicate her opposition to the policy. The organization is in favor of research and 
development due to the necessity of innovative treatments to be used in search of cures 
for rare diseases, and thus hopes to cultivate a relationship with Pfizer for the benefit of 
the organization's population. 
Summary 
The organizations I have met with over the past week have proven to be valuable assets 
with beneficial insight and networking capabilities. Each is unique in its focus, but the 
common goal of quality patient care results in partnership possibilities of benefit to their 
organizations and Pfizer. The groups have all been very interested in hearing the status 
of the prior authorization process, since it has the capacity to impact their constituents 
with such gravity. The Share Card is of interest to them as well due to their interaction 
with disabled individuals who are Medicare recipients as a result of their disability. It is 
exciting to see the tie-ins and be able to develop a network of individuals with such 
amazing potential to effect change within their given niches. 
Developments 
The implementation of the prior authorization process is scheduled to go into effect 
today, February 25, 2002. It will be interesting to see if the phase-in approach is 
successful in alleviating the problems experienced during the initial implementation 
procedure. Since the initial implementation, contact with the voluntary health 
associations and senior centers has been solidified through the initial coalition meeting 
and follow up communication, and through this network we hope to be able to 
communicate the experiences of individuals who are adversely impacted to state 
government officials as quickly and efficiently as possible. 
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TO: Dr. Harold Black 
Dr. Bob Cunningham 
Dr. David Tandy 
FROM: Hannah Kiser 
DATE: March 4, 2002 
RE: College Scholars Senior Project Report 
Report 
The coalition in opposition to the prior authorization policy implemented by the state on 
February 25, 2002 is now at the point of incorporation. Last week the government policy 
firm under contract with Pfizer in Michigan drafted the articles of incorporation for a 
group titled 'Senior Citizens for Prescription Drug Fairness'. At the direction of the 
Manager, State Govemn1ent Relations, I extended offers to participate on the leadership 
con1mittee of this organization to four individuals, two senior center representatives and 
two voluntary health association representatives. One representative, who works with the 
Visiting Physicians Association, the largest home care physician network in the nation, 
accepted promptly and is excited about the position. In addition, one of the senior center 
representatives who had asked that a presentation on the Share Card be made at the 
Senior Leaders conference and also attended the initial coalition meeting has agreed to 
serve. The other two individuals have yet to respond and are waiting for a formal written 
offer detailing the leadership position. 
The Share Card shipment that had been temporarily delayed due to the overwhelmingly 
positive response the program arrived this week. Thus, over 3000 brochures were 
repackaged and mailed out in the requested quantities to those represented at the coalition 
meeting and others who were unable to attend that day. A few of the sixty plus 
organizations that received brochures have already utilized this initial supply and are 
sUbmitting requests for additional brochures. 
The contracts for the consultant firms engaged in the campaIgn against pnor 
authorization were found to need revision, and after this project was completed, they 
were forwarded to the campaign coordinator for his final review. 
The President of the Maria Madeline Project, the intergenerational technology program, 
submitted a proposal detailing the possible partnership with Pfizer. I sent this proposal to 
the New York office of Civic Affairs to be reviewed by the grant review committee. This 
committee regularly considers all philanthropic partnerships presented to Pfizer and will 
determine whether or not moderating the ExperienceSeniorPower chat room opportunity 
will be pursued. 
A regional meeting with the Western counterparts called for presentation materials on the 
status of supplemental rebates in different states. I assisted with the graphics in the 
presentation, which provided an overview of the current situation in California, 
Michigan, Florida and Illinois. 
The representative from the Juvenile Diabetes Research Foundation International had 
inquired as to which insulin treatments required prior authorization. I located this 
information on the changes to the Michigan Medicaid formulary and sent the requested 
information. 
Developments 
On Friday, March 1, 2002, one of the district managers informed our office that a 
member of the Pharmaceutical and Therapeutics Committee had relayed that Zoloft and 
the other drugs in the SSRI class had been carved out from the prior authorization policy. 
The behavioral drugs are now to be grand fathered in, and only those individuals who are 
receiving prescriptions for the first time will be required to go through the prior 
authorization process. This was a notable development, but has not yet been confirmed 
with the state Medicaid office. I placed calls on Friday to the appropriate state employees 
to verify the assertion, but have not yet been able to confirm this change to the policy. 
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Summary 
The campaIgn against pnor authorization is continuing to develop, however, 
simultaneously negotiations with state officials regarding alternative solutions are 
underway. While no consensus on this front has yet been reached, both sides are 
attempting to find a solution. It would be advantageous to reach a compromise without 
the full blown campaign due to the possibility that such a canlpaign has the inherent risk 
of alienating the state and prompting those implementing the policy to become further 
entrenched in their position. Due to the uncertainty of the negotiations, the consultants 
and the coalition are still fully engaged and prepared for a campaign. 
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TO: Dr. Harold Black 
Dr. Bob Cunningham 
Dr. David Tandy 
FROM: Hannah Kiser 
DATE: March 11,2002 
RE: College Scholars Senior Project Report 
Report 
The week began with a presentation over lunch to employees, including physicians, 
pharmacists and other staff of one of the Community Mental Health facilities in the 
Lansing area. These individuals are most directly involved with Medicaid patients in 
need of mental health care and in this capacity have had experience with the prior 
authorization process firsthand for an extended period. Their reports confirmed that the 
process has serious ramifications for mental health patients, and they were interested in 
drafting a document so that they could track the prior authorization process in a uniform 
manner. They raised the issue of the patient's right to appeal and exchanged suggestions 
on how to submit a prior authorization request so that it would have a better chance of 
being approved. 
In meeting with the Michigan Psychiatric Society, I learned that the state had postponed 
the implementation of the process the first time due to the fact that they had not given the 
Medicaid recipients the federally mandated ten days notice. In addition, the vague nature 
of the letter that was subsequently sent to Medicaid recipients left many in a state of 
panic and confusion. It is reported that the pharmacy benefit manager received over 900 
calls the first weekend from individuals concerned that they would not be able to access 
their current medications. Some individuals even called cabs and showed up at the 
Community Mental Health facilities in hysterics because they were so concerned. The 
seventy-two hour emergency prescription provided for in the pharmacy benefit manager's 
contract is not being honored by some pharmacies due to the inability to be reirrlbursed 
for the expense, and now at least one of the health management organizations has 
implemented a prior authorization system prior to the state-mandated schedule. It is 
rumored that the HMO's, which were supposed to have the prior authorization system 
implemented on April 1, will now not be participating in this program until next year due 
to the disastrous effects experienced on the "fee-for-service" side. As anticipated, some 
primary care providers are now refusing to see Medicaid patients due to the increased 
burden on the physician and their staff. They have been sending these patients to the 
Community Mental Health facilities, where the caseload is already high. The Michigan 
Psychiatric Society representative provided me with infonnation on a public hearing 
being held by the Michigan House's Health Policy Subcommittee on Increasing Access 
to Quality Health Care at which many of the health advocacy groups are planning to 
testify. She also provided a draft of a prior authorization tracking fonn. 
A presentation on the Pfizer Share Card was made to the Senior Leaders Conference on 
March 7, 2002, and the group was enthusiastic about this new initiative. Many reported 
that seniors were already inquiring as to how to enroll in the program and were glad to 
have been able to ask questions and receive program infonnation. The senior leaders 
provided valuable insight on how to improve the program for seniors, such as allowing 
the senior center representative to fill out the application for those seniors who have 
difficulties with such tasks. 
A meeting with the contract lobbyist finn on the incorporation of the coalition was held 
later in the week, and the details of the incorporation were discussed. I received 
acceptances of the invitation to serve on the board of directors from all of the seven 
individuals to whom I extended an invitation. The leadership committee of this 
organization will consist of representatives from the Visiting Physicians Association, 
Michigan Association of Senior Centers, NAACP, Epilepsy Foundation, Health Care 
Partners, National Kidney Foundation of Michigan and the Chronic Illness Coalition. 
This group is excited about their leadership role in the Senior Citizens for Prescription 
Drug Fairness and is scheduled to participate in a conference call in which officers will 
be appointed and the goals of the organization fornlalized on Monday, March 11,2002. 
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In addition, I participated in a conference call of the campaIgn participants. The 
campaign calendar has been determined and the first informational luncheon for senior 
citizens in the Detroit area will take place on March 19, 2002. Some 300 seniors are 
being invited to attend and media will be present to cover the event. The coalition 
leadership will have the opportunity to participate in this event. 
The Seniors Coalition is planning to file their amICUS brief on the side of the 
pharmaceutical companies in the lawsuit against the state within the week. The group is 
also presenting policy socials at senior centers throughout the state on the prior 
authorization issue and will conclude with a press conference in one of the state senator's 
offices tomorrow. This group is opposed to prior authorization and has been extremely 
active in informing the senior population about the possible negative effects of this 
policy. 
Developments 
Confirmation of the grandfathering of the antidepressant class was received, meaning that 
individuals who are currently stabilized on such drugs will not be subject to the prior 
authorization process. The state employee overseeing this aspect of the implementation 
has had experience with mental health disorders within his immediate family, and he was 
reported to have said that he would not want his family member to be forced to switch 
medications due to the length of time required to find the proper combination of 
medications. 
Summary 
The alternative solution continues to be explored, however, due to the uncertainty of the 
outcome, the campaign is being implemented. The past week had many promising 
developments and in n1eeting with the various groups, crucial information to the 
campaign against prior authorization was gathered. The health advocates and senior 
center representatives on the board of directors of the coalition are excited about the 
opportunity to serve and will be more formally introduced to each other within the week. 
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TO: Dr. Harold Black 
Dr. Bob Cunningham 
Dr. David Tandy 
FROM: Hannah Kiser 
RE: College Scholars Senior Project Report 
DATE: March 19, 2002 
Report 
The individuals who have agreed to serve on the Board of Directors participated in their 
first meeting by conference call along with the Director of Government Relations, the 
contract lobbyist and myself. At this time officers were appointed, and the goals and 
objectives of the organization, scheduling a Detroit Seniors Day and extending invitations 
to other organizations were discussed. The group also talked about legal aspects of non-
profit corporate involvement and scheduled the first meeting of the board. They were 
interested in targeting legislators who would be influential in the budget process and 
understood the timeliness of the issue at hand. I began preparing a presentation that 
would subsequently be presented to the group on the prescription policy in Michigan. 
[See attached] 
I also met with a mental health advocacy group on the West Side of the state later in the 
week. This group consisted of a city commissioner, several health professionals who 
regularly deal with the Medicaid population, an environmental engineer and mental 
health advocate, a minister and a Medicaid patient. This group has experienced the 
adverse impact of the prior authorization system and is interested in being a part of a 
coalition movement. Although the group has not yet weighed in on the issue, they are 
plarming to organize a public forum to which legislators and other public officials will be 
invited. They extended the invitation for me to attend their meetings on a regular basis 
and also asked to be updated on hearings and other opportunities to testify on the process. 
The Subcommittee on Increasing Access to Quality Health Care held a public hearing 
entitled "Access to Pharmaceuticals." In this hearing, one of the members of our Board 
testified on the prior authorization system on behalf of another coalition of which she is 
part. The Michigan Psychiatric Association, Mental Health Association and Michigan 
Association for Children with Emotional Disorders also provided input on the recent 
changes. The legislators were interested in obtaining definitive data that would indicate 
the current system is not working. 
The Seniors Coalition, a national grassroots advocacy network, completed their statewide 
tour of Michigan with a press conference in the Capitol. The group's spokesperson is 
seventy-nine year old Grandma (Flora) Green. She travels with her staff from state to 
state informing seniors of policies that will impact them and their access to health care. 
In Michigan, they have held policy socials on the prior authorization system and 
partnered with a state senator and practicing physician for the press conference. I was 
able to attend and had the pleasure of meeting Grandma Green. This group is also filing 
an amicus brief in response to the AARP amicus brief filed on the side of the state. [See 
attached article] 
A public policy coordinator from the Civic Affairs division came to meet with me and 
discuss the progress of the coalition. She provided several good contacts and some 
valuable insight on the process of coalition building. The proposal submitted to Civic 
Affairs on behalf of the Maria Madeline proj ect was discussed. This proposal was also 
forwarded to a district manager in the Ann Arbor area for his review. He indicated that 
due to the FDA regulations prohibiting the giving of pharmaceutical advice to anyone 
other than health care professionals, this proj ect could not be pursued. I relayed his 
comments to the Civic Affairs contact so that she would have this feedback prior to the 
submission of the proposal to the grant review committee. 
I also participated in conference calls between the Director of Government Relations and 
the various consultants throughout the course of the week to update them on the progress 
of the coalition, and spoke with members of the field force on the prior authorization 
issue and our efforts. 
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Developments 
The alternative that was drafted by the Senate Appropriations Subcommittee on 
Community Health staff and with input from our office has passed out of the Senate 
Appropriations Committee and is now to be reviewed by the full Senate. This 
compromise would allow the state to receive Medicaid best price for all taxpayer funded 
programs and has the possibility of remedying the current pharmaceutical budget 
shortfall. This is seen as a positive solution for everyone involved. 
In addition, my immediate supervisor has decided to take short-term disability leave due 
to a health condition. This has resulted in an increase in my workload due to the gravity 
of the prior authorization issue. Consequently, I have been asked to participate in 
conference calls more frequently so that his direct supervisor is aware of all current 
developments and have also been trying to keep the consultants up to speed on the 
coalition progress. 
Summary 
The formalizing of the coalition has been a very detailed process with numerous legal, 
financial and personal issues. The group is very vocal and educated on health care and 
senior related issues and I am optimistic that they will be of great value to the cause of 
increasing access to pharmaceuticals in the short and long term. It has been challenging 
to make sure that the concerns and requests of the all of the individuals involved in the 
process are taken care of, since there are occasionally opposing views on how 
information should be conveyed and issues should be handled. 
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TO: Dr. Harold Black 
Dr. Bob Cunningham 
Dr. David Tandy 
FROM: Hannah Kiser 
RE: College Scholars Senior Project 
DATE: March 25, 2002 
Report 
Before the first fonnal nleeting of the Board of Directors for Prescription Drug Fairness, 
an infonnational briefing on prior authorization was sent out via email. The agenda for 
the first meeting was drafted and submitted to both the Director of Government Relations 
and the ChairpersoniPresident of the coalition. The ChairpersoniPresident of the 
coalition has had experience in health care administration and requested further 
infonnation on how similar undertakings in other states have been facilitated. In 
response to this inquiry, a representative from the Pfizer Civic Affairs division in New 
York was asked to be present at the meeting to field any questions along these lines. The 
presentation on the Michigan prescription policy was approved by the Director of 
Government Relations with a couple of minor changes, and consequently an 
infonnational packet for the Board of Directors members was assembled, including a 
contact list, examples of the required prior authorization fonns and a hard copy of the 
presentation. 
I met with the branch manager of the statewide bank chosen by the Board of Directors to 
obtain the paperwork necessary for opening a corporate checking account. He indicated 
that it would be helpful if the Board of Directors menlbers who would serve as signors on 
the account were present at the time the account was opened due to the need for personal 
infonnation. I relayed the infonnation provided by the bank to the Director of 
Government Relations and the Campaign Coordinator by conference call, and they were 
in favor of the ChairpersoniPresident and the Treasurer having access to the funds 
available. 
The first meeting of the Board of Directors began in the morning at the offices of the 
media relations firm in Detroit. Six of the seven directors were present, and the meeting 
opened with the presentation on the Michigan prescription policy. The consultant 
coordinating the campaign against prior authorization was to follow this presentation 
with an overview of the campaign plan, but due to transportation diffculties had to make 
the presentation by conference call. Following his presentation and questions from the 
Board, the government relations firm fielded questions on lobbying requirements. The 
media relations firm then explained the senior luncheon aspect of the campaign. The 
Board concluded the meeting with two motions: the first being the approval of the 
conceptual design of the campaign as presented and the second the scheduling of the first 
senior luncheon in Detroit on April 4, 2002. 
Due to the inability of the Director of Government Relations to be present at this first 
n1eeting, a conference call was held involving all parties who presented to the coalition at 
the first meeting. The general consensus was that the group, in addition to being well 
educated on the issue, was politically astute, and it was agreed that following one more 
meeting they would be prepared to kick off the media campaign at Detroit Seniors Day. 
The second meeting was scheduled for March 26, 2002 at the offices of the government 
relations firm in Detroit. This meeting would involve the Board of Directors as well as 
the Campaign Coordinator, two men1bers of the New York Civic Affairs team, the State 
Government Relations managers from Indiana and Ohio, and the consultants responsible 
for lobbying, direct mail and media relations. The goals of this meeting are to introduce 
all the key players in the campaign, submit the campaign plan to the board for review and 
input, as well as formally establish the coalition. 
Another conference call with the State Government Relations managers from Indiana and 
Ohio was held late in the week to bring them up to speed on the Michigan issue in the 
absence of the Michigan State Government Relations manager. The oversight of the 
Michigan field force was delegated to the Indiana manager, due to his preVIOUS 
employment in that capacity prior to holding the government relations position. 
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Information regarding the prior authorization status of Pfizer products and all previous 
communications from our office to the sales force were forwarded for this purpose. 
Developments 
Unfortunately, one of the directors of the coalition resigned the position late in the week 
due to her organization's conflict of interest on the prior authorization issue. The 
voluntary health association of which she is employed has a large line item in the 
Michigan Department of Community Health budget, which constitutes a substantial 
portion of the organization's operating budget. This organization has historically 
partnered with Pfizer on the state level and was forced to make a difficult decision. She 
indicated that she was personally opposed to the prior authorization policy, but could not 
participate as a representative of her organization. 
Summary 
As the Board of Directors reviews and tailors the campaign against prior authorization, 
they are being directly connected with the consultants involved with the campaign. As 
this progression takes place, my role shifts from founding and organizing interested 
parties to serving as more of a resource for the group as they define their organizational 
parameters. While I provide information and serve as an intermediary for between the 
Board and the consultants, this role is continually diminishing as the consultants assume 
the direct responsibility of their various aspects of the campaign and advise the Board of 
Directors on these matters. 
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TO: Dr. Harold Black 
Dr. Bob Cunningham 
Dr. David Tandy 
FROM: Hannah Kiser 
RE: College Scholars Senior Project Report 
DATE: Aprill, 2002 
Report 
In preparation for Tuesday's coalition meeting, I spent most of Monday gathering 
documents which answered questions raised by the Board of Directors at the previous 
coalition Ineeting. This included a sumn1ary docun1ent of the RFP process by which First 
Health was selected, as well as a list of the Pharmaceutical and Therapeutics Committee 
members who were appointed by the Governor to determine the "best in class" drugs. In 
addition, articles of incorporation were made available for their convenience. 
The second board meeting was extremely productive, despite the inability of three of the 
board members to attend due to illness, prior engagements and religIous holidays. That 
morning I met with the senior account manager of the Civic Affairs division to discuss the 
coalition and the steps that had led up to the current situation. His previous involvement 
with a like coalition in Washington State provided helpful input, and he was able to attend 
the board meeting to give input on how grassroots advocacy had been successful in other 
states. 
Prior to the Board meeting, I met with the Secretary who was unable to attend, so that she 
could sign the necessary bank documents. 
The meeting began with a presentation on the recent grassroots defea~ of a Medicaid prior 
authorization policy in Washington State-a program more restrictive than the current 
Michigan plan. The board members had questions as to how the patient advocacy coalition 
had begun and gained credibility and subsequently discussed opening the membership of 
the coalition to gather a broader base of organizations, in addition to looking into other 
sources of funding. 
A legislative update on the alternative, which passed out of the Senate prior to the Spring 
Break was then given. The alternative would extend the Medicaid "best price" rebate to all 
taxpayer-funded programs. In return for the participation of the pharmaceutical 
companies, each company that chose to extend rebates to the state 1 un programs would 
receive unrestricted status on the formulary. Several pharmaceutical companies have 
indicated that they would be interested in participating in this alternative. The board was 
very supportive of the alternative and felt that it relieved many of the current program's 
issues while providing the state with the revenue necessary to alleviate the budget shortfall. 
The members had input on the prior authorization program's current shortfalls--such as 
inefficient response time; in fact, the Chairperson/President of the coalition had spend over 
thirty minutes on hold when attempting to receive approval for an elderly woman who had 
been stabilized on Glucotrol for diabetes. She felt very strongly that the coalition should 
support the alternative legislation, as did the representatives from the two senior centers 
present. 
The campaign plan as developed with a Senate focus was then discussed, and it was 
decided that such a strategy was no longer relevant. A House strategy was thus drafted 
with the coalition member's input, and the senior lunches as scheduled were cancelled with 
the exception of one. The coalition was conflicted on the issue of media involvement, as 
some felt that they were not yet ready to undertake such a campaign, while others asserted 
that media could play a key role in mobilization efforts. Direct mail pieces were also 
scrapped due to the relatively short time frame within which the alternative would have to 
be advocated. 
The necessary parties signed the bank documents, and I had a bank employee and legal 
counsel review them prior to forwarding them to the treasurer who would open the 
account. Later in the week, I then drafted the unrestricted grant request that would 
ultimately be submitted to the Director of State Government Relations by the officers of 
the coalition and sent it to the President/Chairperson for her review. 
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In addition several conference calls were held between members of the coalition and the 
parties involved in the forming of the coalition. It was decided that regular communication 
between all involved would be the best way to remain up to date on the coalition and other 
aspects of the campaign. The campaign coordinator then formulated a list of tasks to be 
completed by each of the consultants and Pfizer employees in order to ensure that the 
schedule set forth was maintained. 
Summary 
The coalition members are extremely vocal and can be counted on to provide valuable 
input. They are also politically savvy and fully comprehend and consider the scope of the 
implications of their actions. Many of them have been active in advocacy prior to this 
campaign and have significant health care expertise. It is a constant challenge to make 
sure that their questions are answered, in addition to the internal responsibilities. 
Developments 
The coalition members have decided to hold legislative breakfasts within their districts that 
will target the members on key committees with respect to the legislative alternative. 
These breakfasts will include a cross section of health care professionals who can attest to 
the shortcomings of the current prior authorization and the adverse impact on patients, as 
well as the increased staff time required to ensure that quality health care is being 
practiced. These breakfasts will provide a forum for the professionals to indicate their 
displeasure with the prior authorization system and their support of the program that would 
be put in place by the legislative alternative. 
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-TO: Dr. Harold Black 
Dr. Bob Cunningham 
Dr. David Tandy 
FROM: Hannah Kiser 
RE: College Scholars Senior Project Report 
DATE: AprilS, 2002 
Public Policy Report: Washington State 
Due to the impact of the policies enacted or eliminated by other states on the political climate 
and thus, decisions regarding critical public policy issues in the state of Michigan and others, 
a study of the state of Washington provides valuable insight. Subsequently, the defeat of the 
prior authorization system in Washington can be utilized as a model for a successful 
campaign against prior authorization and as a tool for learning how to advocate appropriately 
against an issue. While an identical outcome is not guaranteed by any means, the process by 
which the ultimate goal was achieved in Washington can be patterned in Michigan following 
careful consideration of each aspect of the campaign, while maintaining a sense of the broader 
Issue. 
The Washington legislation included mandatory therapeutic substitution, a preferred drug list 
and prior authorization which is similar to the current Michigan prescription policy mandating 
prior authorization for all drugs not included on the preferred drug list or explicitly 
grandfathered. The initial response in Washington to these impediments to access was an 
attempt to amend the bills so that they would be more palatable; however, when this tactic 
proved unsuccessful, the goal became to eliminate the legislation. The negativity of the 
public policy was emphasized, as well as the potential to adversely impact other states that 
might follow Washington's lead. The following is a more detailed analysis of the actions 
taken in Washington. 
Efforts were coordinated on a number of fronts including the print media, the biotech 
industry, Voluntary Health Associations, the NASDAQ, Pharmaceutical Research and 
Manufacturers of America and the Pfizer sales force. Through the collaboration of these 
groups, a groundswell of opposition to the policy was evidenced, leading to the ultimate 
demise of the policy. Those opposing the legislation would support measures such as targeted 
disease management in hopes of reducing long-term costs and enhancing the quality of life, as 
opposed to restrictive measures focusing more on the short ternl. 
The policy was not opposed by all; in fact, some key groups supported the changes, including 
the local chapters of the American Heart Association, American Lung Association and the 
American Cancer Society, along with the state medical association, pharmacists and labor. 
These supporters based their position on the need to do something to address the rising cost of 
pharmaceuticals, a consideration undisputed by many of the opponents. 
A voluntary health association coordinator was employed to hring together those 
organizations opposing the policy, among them: the American Diabetes Association, Epilepsy 
Foundation, National Alliance for the Mentally Ill, Paralyzed Veterans of America, National 
Association of Black Veterans and others. In addition, position papers were written by the 
National Venture Capital Association and the biotech industry asserting the belief that the 
policy would have a negative impact on the economy. Seattle is one of the two largest 
national biotech markets; thus, an interest in the effect on this aspect of the economy was no 
doubt of great inlportance to legislators and other state officials. 
The National Alliance for the Mentally III undelWrote the cost of transporting members of the 
minority community to Olympia in order to testify to the legislature. The press characterized 
this action as "playing the race card," which was promptly answered by an opinion editorial 
asserting that legislators were attempting to minimize the legitimacy of the issue. 
Consequently, the minority press opposed the legislation, and members of the minority 
community effectively lobbied their state legislative officials. 
The sales force was informed through several action alerts providing them with form letters to 
distribute to physicians and their staff, so that these individuals could express their 
dissatisfaction with the changes in the health care delivery requirenlents. Talking points were 
developed regarding the economic, political and social implications of the policy and were 
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distributed to various audiences, including the GOP caucus. These documents detailed the 
difficulty presented to individuals seeking an exception to the policy, as well as, the minimal 
dollar figure anticipated in savings by the state of Washington. 
An alternative was also proposed, which invalidated the assertion that the phannaceutical 
industry will not advocate options resulting in savings to the state. In fact, the contracting 
finn identified over $50 million dollars that could be saved by the state of Washington 
through the enacting of programs that would not inhibit phannaceutical access. 
Clearly, similarities exist between the Washington and Michigan policies, such as: 
• Restrictions to phannaceutical access 
• Minimal savings being realized by the state through changes enacted 
• Adverse impact on Medicaid population, especially the minority community 
• Mixed review among voluntary health associations, with strong groups represented on 
both sides of the issue 
• Alternative legislation which offers a solution to the current issue 
It is important to note as well the conflicted media messages that fueled the issue and 
increased the public's awareness. While some print media in Michigan has covered the issue, 
polling indicated that much of the public is currently unaware of the two-tiered health care 
system created by this type of policy. 
The response to the Michigan pnor authorization has mirrored that of the Washington 
reaction, in that an alternative has been proposed and is now being considered by the 
legislature through the budget process. It is advantageous to assure legislators of the necessity 
of supporting this alternative. At the current time, members of the House Appropriations 
Committee are being invited to legislative breakfasts initiated and coordinated by directors of 
the Senior Citizens for Prescription Drug Fairness to ensure that the issue is appropriately 
understood and addressed by the legislators in the budgetary process to come. 
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TO: Dr. Harold Black 
Dr. Bob Cunningham 
Dr. David Tandy 
FROM: Hannah Kiser 
RE: College Scholars Senior Project Report 
DATE: April 15, 2002 
Report 
The Michigan Department of Community Health presented their budget for the fiscal 
year 2002-2003 on Wednesday, April 10 to the House Appropriations Subcommittee on 
Community Health. The Michigan Pharmaceutical Best Practices Initiative consumed 
the majority of the discussion, and the Department released a twelve-page document that 
provided their analysis of the prior authorization program's results to date. In addition, 
the Department asserted in their testimony that there had been no appeals or con1plaints 
of negative consequences resulting from patients being switched from a restricted drug to 
an unrestricted drug. They anticipate that the volume of calls to First Health will 
decrease as compliance with the preferred drug list is achieved and indicated that calls 
with technicians now average between three and a half to five minutes per call. 
When asked about the cost savings being realized by the state, the Director commented 
that the program had only been in place a few weeks, and consequently, he would prefer 
to disclose this information at a later date. Questions were also raised as to how the drugs 
were selected for preferred status, whether or not cost considerations were formally 
utilized in this process, and the reasoning behind the lack of public input. At this point in 
time, control groups have not been employed to ascertain the effect of the program on 
Medicaid patients. Interestingly, a recent study by the Center for Studying Health 
System Change, which is funded by the Robert Wood Johnson Foundation, indicates that 
barriers to access such as prior authorization, prescription limits and step therapy have a 
higher impact on the Medicaid population due to low income and chronic illness 
considerations. [See Plint Media.] 
Public input hearings will be held on April 17, 2002 and April 24, 2002. This will 
provide health care professionals and consumers the opportunity to present their 
experiences with the prior authorization system. 
I met with the Mental Health Advocates group in Grand Rapids later in the week, at 
which time I was able to inform them of the current alternative legislation. Several 
individuals were extremely suppoliive and plan to attend the public input hearings to 
rebut the testimony given by the Department. I also extended invitations to the 
legislative breakfasts in their districts, and they are interested in attending these as well. 
Another topic of discussion at the meeting was the Medicaid waiver which would draw 
down federal funding--allowing many of the currently uninsured in Michigan to be 
eligible for Medicaid. The waiver has drawbacks, however, and several mental health 
groups are in opposition. 
A representative of the Michigan State Medical Society contacted our office with a 
request for sponsorship of the annual Capitol Checkup. He indicated that this year's 
theme would be pharmaceutical access, specifically prior authorization. When asked 
what the group's position on prior authorization was, he reported that many of the 
physicians are frustrated with the current policy due to the increased burden on their 
staffs. He went on to say that the best solution would be the legislation involving 
pharmaceutical companies paying Medicaid best price rebates to all state funded 
programs as it would replace the prior authorization system with unrestricted access for 
the participating companies. 
In addition, I participated in several conference calls involving both the coalition and 
other groups. Several mental health groups are in the process of setting up a toll free 
number, so heahh care professionals, consumers and caregivers can relay their stories 
about the prescription policy. The volume of the calls would then be used to convince 
legislators that the policy has not functioned in the way the Department presented both 
prior to and after its implementation. The coalition members have located leaders for the 
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small breakfasts with legislators, and it seems that a variety of constituents will be 
present to educate legislators on their experiences. 
Developments 
Up to this point, the Pharmaceutical Research and Manufacturers of America have been 
neutral on the legislative alternative. There have been reports that some of the larger 
companies which provide deep discounts are now in opposition to the legislation and that 
PhRMA may, in fact, oppose the legislation openly. Despite this development, Pfizer's 
position would remain unchanged, and the campaign against plior authorization would 
continue without alteration. PhRMA is not advocating any other solutions or alternatives, 
and would simply be in opposition to both the current policy and the alternative. 
Summary 
The campaign against prior authorization has evolved into advocacy for the alternative 
legislation. The representatives with whom breakfasts have been scheduled were the 
most inquisitive of the Department at the hearing, and it has been reported that many 
legislators feel as if the Department had misled them regarding prior authorization. The 
legislative breakfasts, opportunities for public input and toll free number should provide 
means for the public to communicate their displeasure with the enacted policy. The 
process of informing legislators is now in action, and the outcome of this process will 
primarily determine the ultimate conclusion with regard to pharmaceutical access in the 
state of Michigan. 
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SPECIAL ARTICLE 
EFFECTS OF ~lEDICAID DRUG-PAYMENT UMITS ON AD~lISSION '.1'0 HOSPITALS AND 
NURSING HO~IES 
STEPHEN B. SOUM'ERAJ, Sc.D., DENNIS ROSS-DEGNAN, Sc.D., JERRY AVORN, ~1.lJ . , 
THOMAS J. MCLAUGHUN, Sc.D., AND leaR CHOODNOVS:KIY, B.S. 
Abstract Background. Many state Medicaid programs the 35 percent decline in the use of stUdy drugs after the 
limit the number of reimbursable medications tt1at a pa- cap was applied was associated with an increase in rates 
tient can receive. We nypotheslzeu that such limitatione of adm.i~~inn to nursing homes; no changes were ob-
may lead to exacerbations of illness or to admissions served in the comparison cohort (AR = 1.8; 95 percent 
to institutions where there are no caps on drug reim- confidence interval, 1.2 to 2.6). There was no signifi-
. bursements. oo.ntly increased ri~k of hospitalization. Among the pa-
Methods. We analyzed 36 months of Medicaid claims tients in New Hampshire who regularly took three or more 
data from New Hampshire. which had a three-drug limit study medications at base line, the relative risk of ad-
per patient for 11 of those months, and from New Jer~ey, miesion to a ntlrsing home during the period of the cap 
which did not. The study patients in New Hampshire was 2.2 (95 percent confidence inteNaI. 1.2 to 4.1). and 
(n = 411) and a matched comparison cohort in New Jer- 1ne risk of hospitalization was 1.2 (95 percent confidence 
sey (n II: 1375) were Medicaid recipients eo years of age inter/ai, 0.8 to 1 .fi} . When 1he cap- was discontinued 
or older who in a base-line year had been taking three after 11 months, the use of medications returned nearly 
or more medications per month, including at least one to base-line levels, and the excess risk of admission 
maintenance drug for certain chromc diseases. Su.vival to Q nureing home Ct;l:;l~P.rl . In general. the patients who 
(defined as remaining in the community) and time-series were admitted to nursing homes did not returnto the com-
;:'n::tlyses were conducted to determine the effect of the munity. . 
reimbursement cap on admissions to hospitals QmJ Ilurs- ConoJueiom;. Limitif'lD rAimbursement for effective 
Ing homes. drugs puts frail, Jow-income, elderly patients at increased 
Results. The base-line demographic characteristics risk of institutionalization in nurSing homes and may in-
of the cohorts w~re nearly identical. In New H<lmpshire, erC~E:e Medicaid costs (N Engl J Med 1991 ;325:1072-7.) 
CONCERl~ has mounted tJlat cost·containrnc:uL policies implemented during the 19aOs may be 
compromising th~ quality of care and the heahh of 
vulnerable populations, such as poor and chronically 
ill elderly pc:ople, although few studies have examined 
this qucsllOll.1.2 Cha.rgee to the pAden,. ()f monthly 1im-
its on medications a.nd other "optional" services are 
characteristic of most Medicaid programs.3 Although 
such restrictions on specific servit:c::s ~ould incrcQ~e 
admissions to hospitals and nursing homes among 
chronically ill elderly people, this has not been demon-
strated in a controlled study. Decades of chnical re-
search and experience document the effectiveness of 
nlc:lny medication, in tre<' ring hoth acute life-threaten-
ing illnesses and chronic debilitating conditions. ~G 
Lack of compliance with drug therapy has been asso-
ciated wJth increased autul~sion3 to hocpit:).l& and 
nursing homes. 7-10 Logica.lly, then, policies that red uce 
access to effective medications may increase the race 
of adverse clinical outcomes and the accompanyin~· 
costs. . 
In an earlier studyll we examined the dl'ecrs of a 
three-drug pa.yment 1imit, or cap, on the use of med-
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DR.-D., T.J.M.>, ~nd \he Pro.r:rJm for tilt AI\3\ysls of Clinic~1 Stn~gies snd (he 
. DepanmeA( of Medicine. Hi\t'VUd Medie3J Scnoo13Jld Beth lsrncl Ho~pi[~l U .A .• 
1.(' ). RMton. Addrcs.s rt"nnc C'C<\l.Icsts [0 Dr. SOllmerai !It the Dcpurt.'7ICnt of 
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ication~ ~mong 10,734 Mpdica.id patients in New 
Hampshire. Among 860 recipients of three or more 
drugs, the cap was associated with significant reduc-
tions in the recci}.ll v[ several import~t medic:a..tiC'ln~ 
(e.g., 28 to 30 percent reductions for insulin, thiazide:;, 
and furosemide) that were not otTset by incrr:ased OUt-
or-pocket purchases. When a copayment u[ :s 1 jJcr pre-
scription replaced the cap one year later, the use of 
most agenr~ 111lickly approached pre cap rates. 
In that study, dara were not available to measure 
possible changes in usc: of institutional seZ"v·ices. One 
hypOUlt::).lzcd effect of the C3.p wu an in('T"::l~~ in nurs-
ing home admissions, due either to deteriorating 
health or to a desire to shift to an environment exempt 
from rhe cap. If the loss of eS::ic.mla.l ulcdication3 led to 
an acute deterioration in health, one might also expect 
inC"rp.ase(] hospiral admissions . In che current study, 
we analyzed 3.6 months of additional nondrug dairoS 
andenrellment data. from Medica.id to an~wer (he fol~ 
lowing ql.le~tion: Among lnw-incnme. elderly l\ledi· 
caid patiems, is limiting access to medications associ-
ated with increased rates of admission to llursing 
homes and ho:)pnals? 
METHODS 
Study Design . 
This ~tudy u.scd survival (defined as remaining in the eommuci-
ty) and InCC'TruI-'LC:U liL\\,-~c;ric3 o.n.l.ly~~~ eo ev:...lll~[~ rn ..... ITpcts of [he 
drug-payment r~triction. Outcome daa included 36 months UuLy 
1980 caJunc 1983) of p!ltientS' nursing hom~ and hospital inpa.ti,nt 
cJaimD in twn ~r~rl': Mcdic&id proer61ms. \Ve comp:ared Ule rstc: of; 
a.dmission to nursing hOllle3 and hospit.lls before, d1Jrin~ . ana ;J,!ter~ 
rhc c~p in ~ defined cohort of chroniclJly ill dderly' pJticl'l:S in the,; 
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study state (New Hsmpshire) with ·the rate in an idcnticalJy dc6~ed 
eUllat'.u':.uu cohort in ~ JUiCe. 'Without A cop (Ncw Je~cy). 
The three-drug payment limit implemented by New Hsmpshire 
,Medicaid during month. 15 to 25 of the 36-month ,tudy period is 
~mhM in dl"uil in our previous report. U With less than two 
months' notice ta providers ~nd parients, the legjdsrivcly mandated 
cost-containment me~ure restricted most Medicaid p~tients to 
three prescriptioDs per month. After 11 m.onths the cap was eJimi-
n3ced and replaec<l with I cop3yment of 11 per prescription. The 
comp.uUol1 slate, New Jersey. was the only northeastern state 
whose Medicaid program had no cost-wring requirements or pay-
ment limita.ti.ans fOr drugs durlng rhe 4tudy pcricxJ. 
Availability and Quality of Data 
Data on enrollment, the usc of study drugs, and hospital and 
nursing home ildmisslons c~e from the c.'Omputeri%.ed McdicOlid 
msnagement inCo(m~tion systems of the two,tatcs. EnroUmeDc files 
were used to determine the age. so:, race, and category or enroll-
ment of the patients, according to study month. Previow report! 
indicate that data rlOm the Medicaid ma.nageJnent informstion 1)"&0-
tenu arc niply reliClble Qnd v~id Cor ftudyi", the precerib4ng of 
drugs or admi$,ion to nursinG' homes.I%-I' Drug cJsims identified the: 
product. number of units dispensed, patient, and date. 
Fo~ evtry Medicaid rC:-3ident of skiUed-nuTsinl' and intermediate:-
arc ucilities, a monthly caim is submitted by the nursing home 
prO\oider for basic ,ervlCCi. Because the study population 'Was al-
ready eligible for Mcdicld at the beginning of the study, any nUD-
inS' bomc !(sy wDuld automatkally be rclmbursed. Irom the tlrst 
month of residence; we rhus svoided the problml of miuing d~ [~ 
during periods whc:n patients must ~pend their resources in order 
\\1 ,coach eligibility Icvcl~. 
Since all the members o( the scudy cohorts Were eligible for both 
Medicare and Medjcaid. Medicare ws.s the primary p~yer for hospi-
tAl ~rvit:,..\. The Ma:dicaid mana~ent information systems con-
uin. cUta on aU !uch services for which Medicaid paid a deductible 
)Z' coiMunnc:c amount. For the first inpatient sdmission in ea.ch 
spdl of iIInc:5s, Medicaid polyS 3 fixed deductible amounl We used 
the Medicaid data to determine inpstient hospital episodes by iden-
tifying C3ch overnight service delivered :It an acuce c:\re ho!pjt.3.l for 
which the rcimburscd Olmount W:\S greater than or equal to the 
tI~u~iulc oa.UU\ult (\)1' (he cur"nc or pr,vious year. 
OminltJon 0' the Study Groups 
The study groups represcnte<i a vulnerable, noninstilutjon~ized 
popubtion of Medicaid palien" over the agc of 60 who were being 
trea.ted for specific. chronic illnesses at base line. Patients without 
Mcdlcarc coven.ge were Ctcludcd because in New H.lmpsblre, pa-
tients enrolled ollly in Mc:dicsid h3d limits on physicians' scrvicr.s 
~d hospiul cbys in addi.tion to tbe cap on medications, whcre:.s 
these CI1rOlleci iA both Mcdiccid cmd M.dic."\rt ("crouova-" piA-
tier:us) had stable coverage for these: $uvices. PMienu w~re included 
in d1c ,rudy if they had 10 Dr mcre mon[hs of enrollment in Medic.. 
Aid during tbe base-tine year truly J. 1980, to June !SO, 1981); were 
60 years of ~ge or older and enrolled in Mcdicsrc by the Slut of the 
payment cap; were white (to control for the ab,ence of nonwhite 
patients in the New Hampshire cohort>; were living in the commu-
nity at base line, wich no nursing home claims during (he t) months 
.b~fore follow-up began; had an average of three or more prc:scrip-
tions per month and at lcast one prescription per qus.rcc:r during the 
b~'line YC<Ll' <&laY u~cJ aucdjuti,;>n for on(. or morc or hV1: major 
chronic illnesses (dja~tes, heart disease, chronic: obmuctive pul-
mOllary disease and asthma, .seizures, or oondition.s requiring the . 
1~~ or anti~2sul'nf") R,..,.:IIU:,. ,,"t~ti~nr (Ii.lenn..~ .. _~ arr. often unrc-
llilble, 16 the reguJar n:ccip~ before the cap, of .m<:dicatio~ common-
J)' used. to treanhcse illnesses ~erved as markers for them. To elimi-
nate occ~oD.1l uscn ot t.hc:se dru~, we defined rCg\liar users a.s 
p.lticnrs receiving eight or more prescriptions in any caccgory of 
'~rkcr mcdica(ion3 during the ~e-linc: yt:~r7 ~nd at least one per 
,l.Ianct'. 
A pane! of geriatricians, internists, and eUnlcaJ pharmacins iden-
tified !pecific classes of moarker mediations, including antiansinal 
~S'S,loop diurC'tic agents, antiarrhythmic sgcnu, bronchodilalors, t 'nhal~d Jceroid;, in~\alin, :ultico~l:'Ibntc, ~n.ci ::anticonvuL:~t :tsenu, 
l; 'i: 1".1 
hereafter referred to as the core drugs. Medications were cho~en for 
ttudy if choir cuddcn wichdn.w:U w:u; Ji:ble to 'preeiplt~te iMtitu-
tionaliution. Agents were excluded if they were frcquendy used for 
noD targeted 3$ well AS tugt1cd iJlncs!.cs (e.g., bets-blockers are 
indicated for both hypertension snd sn~na), had que:tionablc: effi-
cacy. or were auociated with Jess serious Ic:vds of illness. Thu.s, 
~hhough they l~d to. th~ c:xclusion of some p~tienu with targetc:d 
t11nessc:s, the IUnct a"lteraa for regular drug use saved to increase the: 
baso-line comparability of the study and companson cohorts. 
Regular Use of Other MedlcatJons 
In additioo to the core drugs, we also identified 21 olher class~ 
of drugs c:ommonly us~d to treat chronic health problems. These 
included other al;tnLS to CW\t c~rdiov1scular diseases (diuretic 
ageno, beta-blocken, Other antlhypc:rtensive drug', and potas-
sium supplements); or3l hypoglycemic agencs and diabeces.re.sring 
supplies; psychoactive medications (anxiolytic, hypnotic. 3ntipsy: 
chotic, and IUlcidepr~"o.nt drugo); nonccC'Tc:NdcJ. lu,ciin.Aa.mma.'Ory 
:sgcnts, an~lgesies wich addictive potentbJ, and tnO$c used to 
trest migu.inc; oral s[d'oids; and mediCcltions to trea.t ulcc:n, 
thyroid disordet's. gl.1ucoma. P'lrJdnsonism, ~out. and chronic diar-
rh~. As :I. measure of b.1se-line comorbidiry, we counted the num-
ber of fhese 26 cbsses of drugs for which e:lch member of che study 
groups received eight or more prescriptions in the tslle-Iine year 
nablc I). . 
StandardIzation of Use of Study MedIcations 
To tn.ck drug usc for the differenr study medicacioru, we: used 
~sc-1ine data on the entire: Medic;aid populations of both Iltlltes to 
create an inda of .standardized monlhly doses (Ot each of the core 
me.(llcadons. One stand~rd dose equ!.lcd the medIan numbeT 01' 
milligrams of active ingredient peT month received by all the pa-
tients who filed a claim for each study drug. 
Statistical Analysis 
Using SUMv!l1 analysis, we: meJsuf'td the rate of admission co 
hospltals and numnS' homes In New H..l1npshire and N~ J~r3ey 
during three periods: b.se line (April 1981 to August 1981), the c~p 
(Septembcr 1981 toJuly 1982), and aftcr the cap (August 19B2 to 
June J 983}.I7·16 \Ve ~!;o weul;l.tcd UlO rWtlvc rick.: of inc:titutio.n~l 
Table 1. ease-Line Ch8r3cteristic~ of the Study and 
Comparison Cohorts. 
NI;UI'II.,C .. 
NEW IiAWl'UlIIU! COM"UI~O'" 
STUDY CoHOkT COHOtT 
CIl ..... aJ!'Clme (N - 411) eN" - 1J7S) 
".~( 
Age (yr) 
60-69 27 21 
7~79 43 46 
~80 30 33 
Feln:de seJt 80 80 
Rc!;ulw II)C vC ,",u'c; 
medj'.ltiOlU 
Cardisc 77 86 
COPO ;.nd ::asthl1\ol- 19 15 
aaulin 16 9 
Amico" vuls.aa bi : . - 6 7 
Antico~gl.tlsnts I 2 
Number of slIldy ~di.c31ions 
~ reguwly1 
J 16 12 
2 36 32 
30 ~s 
;:'4 18 27 
~ I Inplllienl epLsodCl during 1S ZJ 
6 mo before oap 
·COPO dcnolC~ chro~ic: ob!U\I(li"" pulmonll)' 4i!CI~~O . 
tThe CQ~ mediC::llja~ ,I,,~!he 21 alhcfcb::c:.: of dnop C~mr.lOl\ly u.~cd 
'''' ,....:-., ,.h~,.;~ "".11,. 1''''' ...... ''''C 
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izati~o and 95 percent two-sided (ont\dc:n~c iUlC4 '0'0113 in the atudy 
grO\lps.'t We used segmented time-series regression mc:>dels to esri-
mate changes in drug use, including a constant tc:rm, a linear time 
tTend, and (CTm~ lV c;)linu.tc: chlU\sec \n the m~n ' .. vel of usc: or c:ore 
drug1 during an "antici~(ory" pt'e~p monch (August 1981) and 
during the cap and copayme1lt periods." , 
RESULTS 
Background Characteristics of the Study Groups 
The base-line demographic characteristics and 
rates of drug use weTe similar in the New Hampshire 
and New Jersey ' grOllp~ (Table 1). The hi,gh propor-
tion of women in both cohorts (SO percent) reflects the 
predominance of women in frail, elderly populations. 
.. In the year before lllc c~p poli 
cy was instituted, approximately 
Q) 
E 
o 
J: 
1.00 
0.95 
~ 0.90 
'iii 
:s 
Z 
~ 0.85 
.~ 
:::l 
o 
0') 
.... 
After the cap W::f~ rp.placed by the $1 copaymc:nt, these 
rates rose almost to base-line levels. 
Effects on Nursing Home Admissions 
The most clearly observable effect of the payment 
r~p in New Hampshire was an increase in nursing 
home admissions (Fig. 1) . The proportions of patients 
entering nursing homes were similar in the study 
s'roups before the: cap: 2.3 pe-Tf'"p.nt in New Hampshire 
and 2.1 percent in New Jersey. After the institution of 
the cap, there was a marked separation of the two 
survival curves showing lhc probability of rCIn.ining 
in the community; by the end of the II-month cap 
All Patients 
• New HampshIre 
- 0 New Jersey 
l~ ~-= I I 
1 
I 
I 
\ 
I 
I 
I 
I 
I 
four out of fivc patients in both 
cohorts were regular recipients of 
core medications indicated for 
heart disease; rar,.~c; of regular use of 
medications for chronic obstructive , 
pulmonary disease and asthma, di-
abe(es, am.l scizurC3 were all simi-
lar, as were rates of usc of anticoag-
ulant agents. The total number of 
classes of drugs taken regularly WCi!i 
slightly higher in the comparison 
rnhort; we controlled for the poten-
tial effects of this difference through 
the stratified analyses reported be-
luw; Although patient-spec:ifir tlata. 
on income were unavailable, both 
cohorts were very poor, with in-
comeS substantially below federnl 
poveny levels; at the time of the 
study, the monthly income of el-
derly recipients of supplemental 
security income who lived alone 
w3.~ about 1'3.')0 in both states.'Zu 
During the follow-up period, simi-
lar proportions of patients (35 
percent in New Hamp:Jhire :u\d 28 
percent in New Jersey) died or left 
the Medicaid program for other 
. ~ O. 80 '-'-....... ..J.-.L......I--LI--'-~~ ........... .-L.-.l--J-..J.-.J-,.IJ.......I. ........ .....I--I-...I--..L..-L....,.j.-"'--"-~ 
reasons. 
Changes In the Use of Study 
Medications 
During the base-line year the 
median n\lmhl":r of standardized 
monthly doses of core drugs per 
month \'I-as stable at 2.8 in New 
Hamp!ilti,lC: and 2.3 in New Jersey, 
There was no change in the usc of 
these agents in New Jersey during 
the study period. in New Hamp-
shire, however! the time series of 
drug 1I~P. dropped by 35 percent, to 
1.9 standardized monthly doses per 
patient per month after the cap was 
instituted (two-~ided P<O Of) 1) . 
E 
Ql 
a: 
a 
.~ 
:a 
Palients Takin9 3 or More Classes of Drugs 
I 
I 
I 
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~ 
o 0: 0.95 
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Base Lim:! Cap $1 Copayment 
Periori 
F'lQure 1. Cumulative Probability of Remaining outside a Nursing Horne. 
Tho top panel show~ the curves for all patients in the New Hampshire (n = 411) an 
New Jersey (n = 1375) groups. The bottom panel shows the curves for patlenl~ wh 
regularly used drugs from three or more classes at base line (n :. 198 for New 
Hampshire and 762 for New Jersey). 
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period, 10.6 percent of the New Hamps.hire patients 
and 6.6 percent of the New Jersey patients had been 
admitted to nursing homes. The difference between 
. the two survival curves during this period was signifi~ 
cant (two-sided P = 0.006), and the relative risk of 
admission associated with the cap was 1.8 (95 percent 
confide.nce intervnl, 1.2 to 2.6). After the cap poli~y 
was discontinued, the use of CQI'e drugs returned al. 
mos t to precap levels and the excess risk of new admis-
SIons to nursing homes ceased, as evidenced by the 
approximately parallel curves. 
Further analyses were stratified according to the 
proxy variable for comorbidity (the regular us~ of S or 
more of the 26 classes of drugs). Again, the rates 
of nurcing home admicsion in the two ~tates were 
similar before the cap began and afttr it was replaced 
with the S1 copayment (Fig. 1). During the Period 
of the cap, however, the excess risk of admission 
to a nursing home was even greater for these sicker 
patients in the study cohort, more than double Ule 
rate in the comparison cohort (relative risk = 2.2; 
95 percent confidence interval, 1.2 to 4.1; two-sided 
P ;:::: o .on04) Ry the- end of the cap period, ~n estimat-
ed 14.4 percent of New Hampshire patients regularly 
taking drugs from three or mO.re classes had entered 
uwsing homes, ~ c.ompa!cJ wilh unly 0.2 percenc of 
such patients in New Jersey. For the patients taking 
drugs from fewer than 3 of the 26 drug classes there 
was no significant ditlerence between the study and 
;omparison cohorts, indicating that the cap's adverse 
effect was most pronounced for the patients who wefl~ 
most disabled. 
'A'e next investigated whether this loss of independ-
ence tended to be perma.nent or temporary. Figure:. 2 
shows trends in the proportions of patients residing in 
nursing homes in (he two study groups. All the pa-
lients were included in this analysis until they died or 
became permanently ineligible. The data indicate that 
nursing home stays were not short-tenn. After the cap 
was instituted1 there was a steady rise in the propor~ 
tion of New Hampshire patients in nursing homes that 
pen:i~tl"'ti lJntil thp. end of the cap pE:riod. By then, 7.7' 
Per10a 
• New Hampshire 
o New Jersey 
F'9ure 2. Monthly Proportions of Study Patients Residing in 
Nu~lng Hom9~. 
The :urves include all New Hampshire (n : 411) all(j New Jersey 
(n = 1375) patients. 
~ . 
0') 
.b 
Q) 
al 
(5 
Z 
o~ 
.?;-CP =~ 
..0'" CIJ~ 0.7 
.aU) 
°0 a: l: 0.6 
4) 
.~ 
7a 
'3 
E 
~ 
o 
Period 
• New Hampshire 
o New JGtsey 
Figure 3. Cumulative Probability of Not Being Hospitalized. 
The curves include the New Hampshire (n = 19B) and New Jer-
sey (n = 762) patients wno regularly used drugs from U'lree or 
more classes at base line. 
percent of the 325 remaining New Hampshire patients 
were institutionalized, as compared with 4.4 percent 
of the 1147 New Jcr3CY patients, cy"Cn thou~ll tIle lime 
series was approxima.tely parallel before initiation· of 
the cap and after its abandonmcnr. 
'Vv"e also calculated the distribution of 1cngths of 
stay among the New Hampshire patients who entered 
nursing homes (ri = 4-6). Among the 37 patients who 
entered nursing homes just before or during the period 
of the cap (for whom 12 or more months of follow-up 
wp.r~ av::tibble until the end of obcerv~tion), 32 per-
cent stayed for 6 months or less and 57 percent had 
stayed for 1 year or more; 90 percent of the long-term 
Te~idclHs wen: :iull in nursing homes during the final 
month of observation. 
EHcot~ on Hospital Adml6Slons. 
Analyses of time to first inpatient hospital episode 
were similarly stratifi~rf arroTding to thc number of 
classes of drugs (he patients toak regularly. Patients 
who regularly used drugs from three or more classes 
had eompl.ro.bJc rates of hq3pitali1;i).ciou. Lcfvl c U1C c;ap 
was instituted (Fig. 3) . .After the introduction .of [he 
cap, there was a moderate trend toward increased hos~ 
pitalization amoogthe New Hampshire patients that 
did not reach statistical significance (relative risk = 
1.2; 95 percent confidenc~ intcrval, O.R fo I h); this: 
trend disappear~d when the cap was replaced with the 
Sl copayment policy (Fig. 3). No increased risk of 
hospit.ui:Z4l.tion:. W'3~ found in the patients who u!scJ 
drugs from few~r than three classes before the cap . 
"DISCUSSION 
Although quasi~experimcntal evaluations of policy 
changes can never provide ironclad evidence of caw:e-
and-effect relations, our results provide strong indica-
tions of a direct relation between the introduction of a 
rhrf'r.drug reimbursement limit, 3. re~ulting reduction 
in the use of medications, and an approximate dou-
bling of the rate of nursing horne admissions among 
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chronically ill elderly }JC1licnts. Rates of :a.dmission to 
nursing homes among the study and comparison co-
horts were similar before the: cap was instituted, di-
verged soon after its introduction, wh<:n the u::;c of 
medications declined, and once again became similar 
aftcr the cap W;lS abanclonp.d. These effects were con-
centrated among patients who regularly used three or 
more study medications, indicating heightened vul-
nerability among patic:ut..:s with more thQn one chronic 
illness. A separate, ongoing analysis in New Hamp-
shire also indicates an association between the rate of 
reduction in drug usc due to the cap and the ri.sk uf 
institutionalization (data not shown). 
Were nu.rsing horn,. ;\rfmissions caused by declining 
health or by the desire to maintain the use of essential 
me:dications, because the: three--drug limit did not ap-
. ply in long-Lc:ru.l care: faciliti~? Since admission r~~­
ords were not available for this study, we could not 
distinguish between these two mechanisms of effect. 
The increase in nursing home admissioIls 4ullong the 
padents at highest risk suggests that the loss of medi-
cations conln have exacerbated preeXisting medical 
problems. However, because patients are ofcen ad-
mitted to nursing homes without e~lier hospitaliza-
Liuu," and given ca.£c reports by Nf':W Hampshire 
Legal Assistance of several patients who were trans-
ferred to nursing homes to avoid the policy's dIect, the 
cap probably precipitatc:<l UU1SU'lS' home: admi&&ion& 
for financial reasons as well. Regardless of which 
mechanism eJ(plained the excess admissions, the eco-
nomic impact of prevenrable institutionalization and 
its effects on quality of life are severe. 
Although we oh~~rvf':d a slighe trend roward in-
creased hospi(alizarion during the period of the cap, 
the absence of a significant effect on rates of hospitali-
zacion dC:iCJVC5 con'lmcnt. Incre.3.~e! in 'the: rtlt~ of h()~­
pitalization may have been too low to be measured 
against the high background rate in a chronically ill 
population. In addition, the me~ure used (ljlllC to 
first hospital episode) is insensitive to changes in the 
rates of rppeated events; we unfortunately did not 
have access to data from the primary payer for hospi-
tal scrvices, Medicare, which would have allowed 
lilUt..-:scl'ic.s MalY3e:J of ~l ;Ldmiss:wns 
The study and comparison cohorts were well 
matched at base line for patterns of drug use, soc, and 
race, as well as nursing home: ant.! InJ;;pital U3C. The 
New Jersey cohort was slightly older and received 
more reguJar medications than thc New Hampshire 
group, but this would be expected to reduce observed 
differences in outcomes. All the patients rccei\'edmore 
than 36 pre&criptions in tnl" hase-line yt:ar. a rate of 
medication use strongly associated . with fair-to-poor 
health in an earlier national study of Medicare benefi-
cianes.22 The increase in llll:: 1 acc of cntry into nUTl~ins 
homes immediately after the initiation of the cap 
makes it less likely that differences in the patients' 
characteristics were responsible loe these effects. 
It is unlikely that other changes in policy influenced 
the observed ch~ne~s in the rates of institutionaliza-
tion. A potential confounder would have had co begin 
\,. 
;tr the initiation of (he cap and end at its termination, 
which is improbable. Since all the study patients were 
eligible for Medicare, they were exempt from the lim-
iu on ho~pit3.1 and physlri~n~' services imposed on. 
non-Medicare patients in New Hampshire during the 
cap period. Changes in the supply of beds might influ-
ence the rate of admission to nursillg hOlllC3.2J How. 
ever, the supply of nursing home beds per 1000 elderly 
r~oplc in New Hampshire actually declined by 3.5 
percent from 1981 to 1982, the period during 'W ruch we 
observed increases in the rates of admission as com-
pared with those in New J~r~t'.y.Z3 
Previous studies have indicated that the New Jersey 
diagnosis-related-group program initiated in 1980 
probably caused a sHghr decline iu length of stay and 
a small increase of 0.8 percent per year in hospital 
admission rates.a The program, if it had any effect at 
all, wouJd thus have shortened t~e time to first hospi-
tal admission slightly in the comparison cohort, result-
ing in 3. smaller rehtivp difference between the two 
cohorts. 
At present, about one fourth of state ~redicaid pro-
grams have limirs on Ul U!:, reimbursement in effect. 
Our findings raise questions about the clinical and 
economic wisdom of such policies. Our best estimate 
of the excess person-months of nursing home usc jll 
thc study cohort equals the difference between the pro-
portiCln~ of the two study groups res..lding in nursing 
homes each month. During the 22-month observation 
period after the cap was instituted 1 this excess was 
cs(j1ll4lcd to be 1 it pel·!:on-months. rviw~n New 
Hampshire Medicaid's daily reimbursement rate of 
$59 in fiscal year 1982-1983 (the average of the rate~ 
for skilled-nursmg facilities and intc:,nut:uiatc-carc fa 
cilities),2:i chese excess months in nursing homes COS 1 
$310,745. This underestimates the true cosc, since il 
docs not include other incremental expenses (e.g. 
physicians' services) and it assumes no months ir 
nuraing homes beyond tht": (')h~p.rvation period. Addi 
tional increases in hospital and nursing home admis-
sions in other vulnerable populations that we die 
not study (e.g., the: ciuuui,ally mCnt~lly ill) coul, 
raise such unintended costs well over the estimatec 
statewide savings of 5300,000 to $400,000 achieVe< 
by the cap. II 
Changes in health care reimoorsemcnt policies hav 
probably had si7:\hl~ p.ffccts on elderly and low-in 
come patients OVC1" the past decade, but objective dat. 
on their elTects on quality of care are extremely limit 
ed. J:hc c.hiilkugc for rcscarchet':J ;)nd policy rnalc.~l"C; i 
to discover which cost-containment methods are mo~ 
" efficicnt in reducing ineffective care .... 'hile preservin 
access to forms of medical technolOgy chit l Lend. 
both individual pacienrs and socicty as a whole. 
We a~ illucLLcd to Diln Cilden, director at J~N ".;~oci.ltes. r, 
!ltati9tical and dal.\ processing support; (0 flin Griesba~h for c1 
coding :lJld graphic present:ltion of da.ta; to Jerry Gurwlt%, M.l: 
s.ndJonn Fol,.y. Ph:um.D .. for excellent clinic~ ~dvjct; [0 Dr, s~ 
phcn L.lg:\kos for importanc ins.ighrs into rhe ~trucruring 01 t.' 
stati~tic~1 30illy:tis; to the officers and staff of [he N~ fumpsh 1 
and. Ne:w Jersey Mcdiclid programs who supplied the dau; .1n~ 
L<lura. Goldberg for assist3.nce in the prep:H:ldon (Jf lhe 111.mwcr'p 
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Industry Headache 
States Square Off 
Against Drug Firms 
In Crusade on Prices 
~Iichigan's Ne\v Experiment. 
Leads Pfizer and Others : 
To Stage a Boycott 
Vioxx Doesn't ~Iake the Cut 
Efforts by state governments to cut pre-
scription-drug prices are sweeping across 
the nation, posing a serious challenge to 
the U.S. pharmaceutical industry's mighty 
lobbying machine-and to its profits. 
This summer, Florida announced that 
. drug companies participating in its lucra-
tive Medicaid program would need to pro-
vide special rebates. Maine restricted ~led­
icaid access to expensive drugs while sepa-
rately threatening companies with price 
controls if they didn't offer discounts to 
residents who don't have drug coverage. 
And this morning, Michigan plans to re-
lease a list of lower-cost drugs whose 
prices other drug companies. must match 
in order to receive preferentIal treatment 
from state drug programs. 
Pharmaceutical companies are fight-
ing back with lawsuits and adverti~in~ 
campaigns, and rushing to sta~p out ~lml­
lar movements in Louisiana. ~llssoun, In- . 
diana and ~Iaryland. 
But some in the industry say the number 
of cost-cuttinastates may be reaching acrit-
ical mass. "Alone. they can be picked off, 
John Engler 
but if they stand to-
gether, they can win," 
says Diane Rowland, 
executive director of 
the Kaiser Commis-
sion on Medicaid and 
the Uninsured, a Wash-
ington-based health-
policy think tank. 
At stake are poten-
tially billions of dol-
lars in sales, not just 
to states and public-
aid programs but also 
to the private health-
insurance market. which often is influ-. 
enced by new developments in state pol- : 
icy. Equally worrisome to the industry, the : 
latest developments signal that the battle : 
has shifted away from Washington-where 
phannaceutical giants have cultiv~ted 
great influence -and to state capItals 
around the country. where it can be 
harder to fight back. . 
Surprisingly, the most ~amagmg 5alvOS 
haven ' tcome from regulatlOn-nunded Dem-
ocrats but influential Republican governors 
with close ties to the White House. including 
the president's brother. Florida Gov. Jeb 
Bush. and ~1ichigan' s Gov. John Engler. 
"The political wtnds have changed," 
says Arkansas' Medicaid director. Ray 
Hanley, who personally helps speed the 
change by passing word of new develop-
ments with a flurry of e-mails to his col-
leagues. ''I've got all 50 Medicaid directors 
on one button," he says. 
Adds Michigan's Gov. Engler: "Michi-
gan will be a Signal for other states and 
other states will follow." 
The changing climate began as the 
economy sputtered early in the Bush ad-
ministration, drying up states' tax reve-
nues, This forced them to confront the es-
calating cost of pharmaceutical drugs un-
der Medicaid, a federal- and state-funded 
health plan for the poor and disabled. 
States collectively are forecast to spend 
around S2S billion buying Medicaid drugs 
during the current fiscal year. Last year 
their purchases represented about 12Qc of 
total industry sales. 
States were also disappointed when 
Congress failed to pass a prescription-
By Wall Street .Journal staff reporters 
Russell Gold in Lansing. Mich., Scott 
Hensley in Nelc York and Andr~u.: 
Caffrey in Boston. 
drug benefit in :\Iedicare, a health plan for 
the elderly. While the states don't help foot 
the :\Iedicare bill, as they do with ~ledic­
aid, most have programs to help the eld-
erly pay for their prescriptions. For states. 
pharmaceutical drugs were no longer _~ 
footnote in their budgets; they were 
quickly becoming a major line item. 
In July, Florida became the first state 
since federal Medicaid laws were over-
hauled in 1990 to extract additional price 
concessions from drug makers. Under fed-
eral law, pharmaceutical companies that 
sell to state Medicaid programs must offer 
them the same prices they give their most-
favored customers. Florida took this a step 
further, generally requiring companies to ' 
offer rebates averaging around SC:c on top 
of those already-discounted prices. 
:\Iichigan's experiment is potentially 
even more serious, because it expands 
well beyond ~Iedicaid-funded drugs, and 
because it takes dead aim at drug compa-
nies' freedom to set prices. Instead of tak-
ing as a starting point the prices offered to 
companies' most-favored customers, the 
~lichigan experiment seeks to drive all 
prices down to a low common denomina-
tor. A similar movement in Europe, known 
as "ref-erence pricing," has savaged drug-
company profits there. 
In :\[ichigan. it works like this: A com-
mittee of 11 doctors and pharmacists, 
meeting privately in a windowless base-
ment conference room. chose so-called 
"best-in-class" drugs in -to categories that 
would get special treatment in the S1.1 
billion the state spends each year on pre-
scription medicines. 
The selected drugs will be guaranteed 
a handsome slice or the state expenditures 
in both :\ledicaid and J state-funded pro-
P'r'([SI:! T~ lI'?1 to P'7.IJI! ...I.U. CO/limn I 
States Clash With Drug Industry 
Continued From First Page 
gram for the elderly. Doctors can pre-
scribe drugs that aren't on the list but only 
after justifying their decision in a call to a 
phone bank of pharmacy technicians - a 
requirement expected to discourage use of 
those drugs. Thus, all companies wanting 
to sell drugs under these programs risk 
losing market share unless they agree to 
slash prices to also win a spot on the pre-
ferred list. 
An early preview of the list shows that 
several of the biggest drug makers will be 
hit hard. Among pain relievers commonly 
prescribed for arthritis, for instance, ge-
neric ibuprofen and generic naproxen 
made the preferred grade, while the 
widely prescribed . Celebrex, jointly mar-
keted by Pfizer Inc. and Pharmacia Corp., 
and Vioxx from Merck & Co. didn't. 
Although the state won't detail the p0-
tential savings, they appear to be large. 
According to Fred Ghannam, owner of 
Capitol PhaI1Ilacy, about one block from 
the state capitol building in Lansing. the 
retail price of a month's supply of generic 
prescription-strength naproxen is around 
521, while a comparable prescription for 
Celebrex is $151. 
Lumping the Old and the New 
Drug makers complain that the pro-
gram is flawed because bureaucrats lump 
old and new drugs together, declaring all 
medicines in a given category to be equiva-
lent. This thwarts industry efforts to differ-
entiate their newest wares-and, they say, 
gives them little incentive to spend money 
on research and development. 
The industry's counterattack has been 
swift. Last Friday its trade association 
filed suit-the group's fourth against a 
state government in the past 16 
months-seeking to block the Michigan 
program, scheduled to go into force in Jan-
uary. Meanwhile, six major drug compa-
nies refused to play by Michigan's new 
rules, declining to make any price conces-
sions to guarantee a spot on the state's 
preferred list, or fOI1Ilulary, for those 
drugs not selected best in their class. 
"We think they've gone too far," says 
Charles Hardwick, a senior vice president 
for government affairs at New York-based 
Pfizer, the world's largest phaI1Ilaceutical 
company, which declined to participate in 
the Michigan price-cutting program; 
Early results from other states that 
have adopted programs less restrictive 
than Michigan's show both the potential 
upside for states and possible downside for 
companies that don't cut prices to get on 
the states' preferred lists of drugs. . 
Florida expects to save at least S100 
million this fiscal year. At the same time, 
sales to ~Iedicaid of several drugs not on 
Florida's preferred list have plummeted: 
The market share of AstraZeneca's heart-
burn drug Prilosec in Florida dropped to -1% 
from 38% in the first three months since the 
preferred list went into effect, while Pre-
Over Price Controls 
vacid, from TAP Pharmaceutical Products 
Inc., Lake Forest, Ill., saw its share rise to 
65% from 43% over the same period. 
Drug companies worry that doctors out 
of sheer habit will be more likely to pre-
scribe Medicaid-preferred drugs to their 
non-Medicaid patients, as well. At Miller 
Drug of Bangor, Maine, which fills more 
than 1,000 preSCriptions per day, phaI1Ila-
cists say they're seeing just such a trend. 
For instance, after Maine selected Madi-
son, N.J.-based American Home Products 
Corp.'s Protonix as its preferred heart-
burn drug beginning this year, the medi-
cine was dispensed for nearly 75% of Mill-
er's Medicaid heartburn prescriptions, up 
from just 3% three quarters before. There 
was a smaller but still-noticeable increase -
for the rest of Miller's customers. Protonix 
was the dispensed drug for 13% of heart-
burn prescriptions, up from 3%. 
The industry is fighting back most vig-
orously in the courtroom. As MiChigan offi-
cials were developing their plan, the Phar-
maceutical Research and Manufacturers 
of America, the Washington-based indus-
try association known as PhRMA, filed a 
lawsuit against Florida in federal court in 
Tallahassee. The group argued that fed-
eral law allows states to limit access to 
Medicaid drugs only if they offer no clini-
cal benefit, not if the manufacturer 
doesn't offer a large enough price cut. A 
hearing is scheduled for today. 
"The state litigation is unique to the 
last few years, because states are becom-
ing more aggressive in trying to regulate 
pharmaceutical prices," says PhRMA as-
sistant general counsel Marjorie Powell. 
So far, PhRMA has won only one 
case - killing a Vermont effort to use Med-
icaid to provide drug coverage for noneligi-
ble seniors. But the suits have had a chill-
ing effect. Iowa and California are launch-
ing efforts to get drug companies to volun-
tarily offer discounts to seniors, partly be-
cause mandatory price-cut programs have 
sparked industry lawsuits. "If someone liti-
gates-rightly or wrongly-it puts a stop 
to what you're dOing. YO.U cannot move 
forward," says Dr. Carol Kuhle, chair-
woman of the nonprofit corporation Iowa 
created'to run its new program. 
The industry was slow to marshal 
forces to fight the Michigan program be-
cause state officials deliberately concealed 
what they:were up to for several months, 
Faced with Medicaid and other state-
funded drug costs that doubled to S1.1 bil-
lion over the past two years, state health 
officials needed to find 542 million to plug 
a hole in their new budget and find some 
way to control escalating pharmaceutical 
costs long term. James Haveman, director 
of the community health department, 
which runs Medicaid. was convinced that 
~Iaine and Florida were heading in the 
right direction but wanted to go farther. 
In June, he proposed to state lawmak-
ers that the mandated price cuts be ex-
panded beyond ~Iedicaid to also cover the 
~I 
.. 
state's senior drug-assistance program 
and other state-funded programs. But 
state Rep. Mickey Mortimer, chairman of 
a subcommittee handling this piece of the 
budget, balked. "I wanted to be sure we 
didn't put anybody at risk," he says, wor-
ried that patients would be denied access 
to needed drugs_ 
Novel Approach 
With the budget at a standstill, Gov. 
Engler intervened, calling Mr. Mortimer 
and other top lawmakers to his office. Mr. 
Engler suggested a novel approach: pass a 
budget with broad language authorizing 
unspecified phannacy practice changes by 
the end of September. In the meantime, 
state health officials would develop the spe-
cifics of the program. If Mr. Mortimer or 
his counterpart in the state senate didn't 
both like the resulting program, they 
would have a chance to block it. Within 
five minutes, a deal was struck. 
During the three months he had to de-
velop a plan, Mr. Haveman decided he 
didn't want to be slowed down by pharma-
ceutical companies applying lobbying pres-
sure. He instructed his top deputies not to 
meet with or take phone calls from drug 
makers.' 
"I needed time to think and plan," says 
Mr. Haveman. 
It was another lesson learned from 
other states, where intense industry lobby-
ing had killed drug-rebate proposals. "The 
states have learned that if they are going 
to be able to negotiate deals and work 
against the drug companies, they have to 
do it behind closed doors," says Ms. Row-
land of the Kaiser Commission. "If they do 
it in too open a way, they will be lobbied to 
death:' 
Industry officials were livid. "This was 
handled with speed and deception," says 
Stephen Scofes, the Lansing-based lobby-
ist for Eli Lilly & Co., Indianapolis, and 
Merck, who tried unsuccessfully to sched-
ule a meeting with Mr. Haveman. 
On Sept. 28, two days before the dead-
line imposed by the state budget, state 
health-department officials disclosed how 
its preferred list would be put together. 
Mindful that Florida's program had been 
sued by PhRMA for basing its list mainly on 
discounts offered by drug makers, Michi-
gan's lawyers suggested a different ap-
proach: A committee would justify its deci-
sions based on clinical grounds. During 
three meetings, the committee scoured sci-
entific journals and debated the benefits of 
drugs in 40 categories that account for the 
vast majority of state drug expenditures. 
In early October, First Health Services 
Corp., a suburban Richmond-based subsid-
iary of First Health Group Corp., Downers 
Grove, Ill., contracted by the state to ad- -
minister its pharmacy program, invited 
the companies to meetings in Richmond, 
Dallas and Lansing to tell them what dis-
counts they would have to provide for their 
drugs to gain preferred status. 
Drug companies say they were left in 
the dark during the crucial process that 
defined the categories of drugs and se-
lected the so-called best-in-class drugs . 
"When we met with First Health Services, 
we discovered that, in fact, none of the 
terms of the agreements were open to ne-
gotiation," David Marin, an vice president 
for at Peapack, N.J.-based Pharmacia 
Corp., later wrote to state officials. 
On Nov. 13, the day before lawmakers 
gave their final approval, Merck advised 
the state it would refuse to offer any re-
bates. Pfizer, Eli Lilly, Phannacia, Johnson 
& Johnson, New Brunswick, N.J.; and Wy-
eth-Ayerst Laboratories, a unit of American 
Home Products, quickly followed. 
On Nov. 30, PhRMA filed its lawsuit in 
state court.in Lansing, alleging the way in 
which Michigan adopted the program vio-
lated the state constitution and state laws. 
Both sides are taking risks. The six 
boycotting drug companies stand to lose 
market share to competitors that agreed to 
cut prices to get on the state's preferred 
list. But if doctors or patients balk because 
some of the six firms' most-prescribed 
drugs aren't included, that could force 
Michigan to back away from its program. 
Whicheve~, side prevails, says Arkan-
sas' Mr. Hanley, other states are watching 
the battle closely, to help plot their next 
move. "If a huge state like Michigan can't 
do this, then smaller states like us proba-
bly can't either," he says. "I'm pulling for 
Michigan." 
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Injunction Blocks Michigan ~Iedicine Law 
BI,' : ~ ill:;~l,:t.ll Go(.n 
Se(vf RCp'.rc~,. "." "'" W"t.' :)"I~I'~" JO\ ;I,N ,'. 
In (l victo'~ lor the pharmaceuticals 
inclust:-/. a 1\1 ich:llan judge yesterdJY is· 
sued a prelinlirl'~;'Y mjunction to block () 
stace l:-..w th ;t t ,'leeks price concessIons 
tram drug cc,'nl'i.l lies in exchange lor In· 
cJusior. on 11 1 s:, (, f preferred drugs, 
The lawsu't V"I~S med by the Pharma· 
ceutlcn,l Rese;~rrl ' and McinUrd.cturers of 
AmericJ.. a W~ll ngton trade group. The 
group. knowlI 0: PhRMA, orposes the 
gt'owing numl: el' r f stlte efforts to restrict 
access to prc~ c'illtion cJru~s as a way to 
control risIng h ~;.\\th·c(\rc costs. 
Under the [Ir>l')sed Michig,\n progrnm. 
doctors must ca.lll,) seek permission to pre-
scnbe drugs thil r I~ren 't on the slate's pre· 
ferred .:i1'Ug list . ~f!' le preferred·drug law cov-
ers 1.6 ~llllon 'lE (. IIle in Medicaid and other 
state,!u:lded tlchU: 1 programs. 
In his order g' '~1I1tini the Injunction. Ing· 
ham Countv C X,:\I ; t Court Jl!dge Lawrence 
M. G!a;:~r r\.:l, d II. Jt the unorthodOx man-
nero! Ir."'.plemt~nllig the Michigan lllw-scv, 
ern.: prcr.1inem I ~';Iisl~tors were glven what 
a.moun~~d co l~ v~~lto over the pollcy after 
Gov. Jchn En~~ler ::rgncd the l«w-violjt~d 
the st,\.~e conSI it ull ion. The judge ;'llso was 
pers\la~~cl b~1 ~'r'lIliments trom scverJI 
gToups :-~presl:ni' ~ the mentally ill thaC re-
strictir.;; a:ce~ ; lo,:ertJin drugs could Ilium 
patients. The j . 1(11~·!~ l:!ltowed those group.:i to 
jam the lc\wsul t. 
The :'.tichiF'nn IDep:l.rrm~nt of Commu· 
nity He=.lth ha 'i :1I:!d Iln emergency appeal 
to the srl.tc ~pr ~~ ' lIt\tc court a.nd hopes to " 
stil! be able to ITHI'i ,ement the prerelTed list 
on Jan. l~. a~ rl:.h1ned. , 
Thp state's )rc ,('!rred·dnli list W,\S devel· 
oped by a coml"l :"1 e of physicians and ph~lr' 
macis rs who m1~t lil,;t (nn to select It least two 
"best·in-class'· d:"I~s in 40 diCfcrent c~tcgo· 
ries. These drug:; ' . ."ould go on the preferred 
list. Alt ~rherdrul=~· ,.vould mllke the ::>referred 
ltst onlv tC the n a -.(I :·S cut theirpl'ices to equal 
the :owe~t-pt1c, d "Ilest" dru~. Several compa-
,. .:, ...... 8 '02 19: 15 
nics. indllcting Ptilt'r Inc. amI Mer!:\( &.: Co. 
l'efusccllo offer any price breaks. 
The Michigan decisIon comes just d.1Ys 
after a federal Jl1dge let stand J. simllar 
program implemented last yenr in Flor-
Ida. Alrea.dy, other states seeking budget 
savings are hoping to copy FlorIda, This 
week Colorado l~wmJ.kers plan to intro· 
duce a bill, modeled on Florida's program. 
to seck additional rebates Cor Medicaid 
drugs. TIle bill's spensor, Sen. Penfield 
Tate. Suys he WIlS encouro.ged by the Flor· 
ida !ederal-court rullng. PhRMA has ap-
pealed tile Florllhl Clse to the Eleventh 
U.S. Circuit Court or Appeals in Atlanta. 
PhR),{A W:lS pleilsed with the Mlchig:l.n 
ruling. Jan Faiks, assistant general counsel 
for PhR..'AA. says the prererred·drug' list \s 
harmful because it interferes with doctors' 
freedom to prescribe whac they feel is the 
most ilnpropriltc dru~, "The st:ile impos0d 
I tself between the patient and the doctor." 
she says, "We thinl{ thilt Is of tremendous po· 
tentlal harm to the doctor·patient relation· 
ship and ultimately to lhe pltien('s health," 
Mark Reinsteln, vice president of the 
Mental H~alth Association in Michigan. 
one of the groups which joined the la\llstli~. 
says the preferred list "was set up to de· 
prive tham {persons with mental ll1nes:J 
or access to certain drugs and that would 
hurt too many people." -
Geralyn Lash~r. a spokeswoman for ' 
the Michigan Dep~rtment of Community I, 
Health. says if doctors want to prescribl? :t 
certclin dru~, tIle state llW doesn't StOP 
them. It just requires an extra effort. "If a 
drug' is medically necessary, that is thr! 
drug a reCipient will get." Ms, LJ.sher 
says. Michigan expected to Solve )42 mil· 
lion this fiscal year from the prog1'lm, 
- _e, · ' •• e •• • • _ • • •• _. __ • • • • • _ • • , _ ...... _ • • _ • •• •• __________ • __ 
Walt Street:ro~r~ 
Jb..rL~ ~.~OO.9. 
Senior groups square off over Medicaid prescription program 
By DEE-ANN DURBIN 
03112/2002 
Associated Press N ewswires 
Copyright 2002. The Associated Press. All Rights Reserved. 
LANSING, Mich. (AP) - Senior advocacy groups are taking opposite sides in the battle over the 
state's new prescription program for low-income patients. 
The new state program, which took effect Feb. 1, allows doctors to prescribe only certain 
discounted medications to the 1.6 million patients who rely on Medicaid unless the doctors get state 
authorization for medications not on the list. The state expects to save around $42 million this year 
with the program. 
The Seniors Coalition, which has around 30,000 members in Michigan, came to the Capitol 
Tuesday to present lawmakers with a banner covered with signatures of seniors who oppose the 
prescription drug plan. Flora Green, the Seniors Coalition's national spokeswoman, said the 
program could hann seniors. 
"The doctor-and-patient relationship has to be protected at all costs," said Green, 79, who lives in 
Utah. "How can someone who doesn't know me make a decision that supersedes my doctor?" 
On the other side of the issue is the Michigan AARP, which has around 1.4 million Michigan 
members aged 50 and older. The AARP supports the program because it says the state must control 
prescription drug costs, which have reached $1 billion per year. 
"Prescription drug prices can be prohibitively expensive to those without drug coverage, and older 
persons tend to use more medications," Michigan AARP director Stephen Gools said in a news 
release. 
"We believe the Michigan program is a sincere, effective attempt to insure that that state has the 
funds to provide prescription drugs to Medicaid recipients." 
Green said she understood the need to control costs, but said the state should look for other ways to 
cut funding. 
"Does anyone have the right to balance the budget on the backs of seniors?" she said. 
The program is being challenged in court by a coalition of drug companies and mental health 
advocates. The Michigan Court of Appeals is expected to rule this spring on whether the program 
should remain in place. Both the Seniors Coalition and the AARP have filed briefs in that case. 
Meanwhile, state Sen. John Schwarz, R-Battle Creek, is sponsoring legislation that would require 
the state to place practicing physicians, phannacists, drug company representatives and a patient 
advocate on the committee that decides which drugs are on the state list. 
Gov. John Engler appointed the current members of that committee last fall without consulting the 
full Legislature. Drug companies weren't involved in the process. 
"I question the wisdom of the present system," Schwarz said. "I believe it's really quite arbitrary." 
But Schwarz, who is a surgeon, said he does support having a state list and requiring doctors to get 
pennission before prescribing some drugs. Most health maintenance organj'?:ations have similar lists 
as a cost-saving n1easure, he said. 
On the Net: 
The Senior Coalition, http://www.senior.org 
AARP, http://www.aarp.org 
Michigan Department of Community Health, http://www.mdch.state.mi.us 
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Many on Medicaid Lack Drugs, Study Says 
By ROBERT PEAR 
WASHINGTON, April 8 - States have become so aggressive in trying to control 
Medicaid spending on prescription drugs that many Medicaid recipients do not get all the 
drugs prescribed for them, researchers said today. 
Although Medicaid covers prescription medicines in every state, one-fourth of patients 
enrolled in the program reported that they could not afford to fill some of their 
prescriptions in the last year, the researchers said. In an environment of rapidly rising 
drug prices, they said, states' cost-control efforts were the leading factor. 
Most states are experiencing fiscal problems, and drug spending for Medicaid recipients 
has been rising 15 percent to 20 percent a year. So state officials have adopted numerous 
measures to rein in costs - some of them requiring co-payments, for instance, others 
limiting the number of each patient's prescriptions. 
"It appears that a consequence of aggressive cost-control policies is a reduction in 
beneficiary access to prescription drugs," said the researchers, from the nonpartisan 
Center for Studying Health System Change, who were led by Peter 1. Cunningham. 
The study was based on a survey of 39,000 adults, including nearly 1,800 on Medicaid. 
By most measures, it said, Medicaid recipients and people with private insurance have 
similar access to medical care. But, it said, prescription drugs appear to be an exception; 
some Medicaid recipients have almost as much difficulty as the uninsured in obtaining 
medications. 
Twenty-six percent of Medicaid beneficiaries ages 18 to 64 reported that they could not 
afford to get all their prescriptions filled in the last year, the report said. That was just 
slightly less than the 29 percent of uninsured people who reported similar difficulty. 
By contrast, 8 percent of people with employer-sponsored health coverage and 8 percent 
of elderly people with Medicare said costs prevented them from obtaining medicines. 
(Medicare generally does not cover prescription drugs outside the hosnital, but about 
two-thirds of Medicare beneficiaries have drug coverage from other sources.) 
Len M. Nichols, vice president of the Center for Studying Health System Change, said, 
"The findings are surprising because Medicaid is expected to ensure access to affordable 
care for the poorest and sickest Americans." 
Medicaid is financed jointly by the federal government and the states. The states have 
broad discretion to decide on the details of their individual programs, within federal 
guidelines, and all have chosen to cover prescription drugs. Having made that choice, 
states must cover most drugs that have been approved by the Food and Drug 
Administration. They cannot arbitrarily refuse to cover drugs for a particular illness. 
Cost-control methods vary by state. Some states charge a co-payment of $1 to $3 for each 
prescription. Some limit the number of prescriptions, allowing no more than three to six 
in a month. Some require doctors to get authorization before prescribiflg certain drugs. 
Some require the substitution of generic drugs for brand-name medicines, or require 
doctors to try lower-cost drugs before prescribing more costly ones. 
But Ray Hanley, the Medicaid director in Arkansas, which requires co-payments, said he 
found it hard to believe that people were going without prescription drugs because of cost 
controls. "If anything," Mr. Hanley said, "the co-payments need to be higher. The limits 
on co-payments have not changed in 20 years, and many people, including children and 
pregnant women, are exempt from co-payments." 
Joan Henneberry, a health policy expert at the National Governors' Association, said: 
"There's no question that cost-containment measures affect access to prescription drugs, 
but that may be a positive outcome. We know that Medicaid beneficiaries are often 
getting too many medications, duplicative medications from various doctors and, in some 
cases, medications that are contraindicated and dangerous." 
Some of the cost-control techniques used by Medicaid are also used by private insurers. 
But Mr. Cunningham, the lead author of the new study, said these measures were more 
likely to curtail access to prescription drugs among Medicaid recipients because they had 
lower incomes and were more likely to have chronic illnesses. About 40 percent of 
Medicaid recipients with two or more chronic ailments reported that they could not afford 
prescription drugs that they needed, the study said. 
No cost-control technique by itself severely impaired access to prescription drugs, the 
study said. But a combination of such techniques made it more likely that Medicaid 
recipients would be unable to afford medicines, it said. 
In states with four or five cost-control techniques, an average of33 percent of Medicaid 
recipients reported that costs kept them from filling son1e prescriptions, the study said. 
By contrast, 15 percent of beneficiaries said they had trouble filling prescriptions in states 
using one cost-control technique, or none. 
The states with four or five cost-control measures, the report said, are Arkansas, North 
Carolina, South Carolina and West Virginia. 
Issue Brief 
Findings from HSC 
PRESCRIPTION DRUG 
ACCESS: NOT JUST A 
MEDICARE PROBLEM 
by Peter J. Cunningham 
While all state Medicaid programs provide outpatient prescription drug coverage, 
slightly more than one in four Medicaid patients ages 18-64 could not afford to fiU 
at least one prescription in the last year, according to a new study by the Center for 
Studying Health System Change (HSC). A similar percentage of uninsured adults 
also had difficulty affording prescription medications. Faced with rapidly rising 
drug spending, many states have moved to control Medicaid prescription drug 
spending by imposing copayments, limiting the number of prescriptions and using 
other cost-containment methods. The study indicates that these state cost-control 
measures are contributing to Medicaid beneficiaries' prescription drug access prob-
lems. State and federal policy makers should keep in mind that the impact of these 
controls on Medicaid beneficiaries is likely to be greater than on privately insured 
people, given their higher need and lower incomes. 1 
Nonelderly Have Problems AHording Drugs 
~hile recent federal and state policy 
'II debates have focused on the pre-
scription drug needs of the elderly in 
Medicare, many nonelderly adults also 
have problems affording prescription 
medications. According to HSC's 
2000-01 Community Tracking Study 
Household Survey, non elderly adults 
enrolled in Medicaid and those who 
are uninsured have the most problems 
affording prescription drugs--more 
than one out of four people in both 
groups did not get at least one pre-
scription drug in the past year due 
to the cost. This is in sharp contrast 
to those in Medicare and those with 
employer-sponsored private insurance 
(see Figure 1). 
CENTER for STUDYING 
HEALTH 
SYSTEM 
CHANGE 
The fact that adults with Medicaid 
coverage have problems affording pre-
scription drugs is surprising. Medicaid 
is designed to ensure access to afford-
able medical care for the poorest and 
sickest Americans, and all state Medicaid 
programs provide drug coverage for 
most beneficiaries.2 The wide gap in 
access to prescription drugs between 
non elderly Medicaid enrollees and 
those with employer-sponsored cover-
age stands in contrast to other types 
of care. For example, people with 
Medicaid are more similar to those 
with employer-sponsored coverage in 
terms of unmet medical needs, having 
a usual source of care and contact with 
a physician in the past year. 
Low Income, Poor Health 
Compound Problems 
Despite the assistance Medicaid 
brings, beneficiaries' low incomes put 
them at much higher risk of being 
unable to afford prescription drugs. 
Half of nonelderly adult Medicaid 
beneficiaries have incomes below the 
federal poverty level, or $8,590 for a 
single person in 2001 (see Table 1); 
three-quarters have incomes below 
200 percent of poverty. By contrast, 
only 3 percent of people with 
employer-sponsored health coverage 
have incomes below the poverty level, 
while 14 percent have incomes below 
200 percent of poverty. 
State eHarts 
to control Medicaid 
prescription drug 
spending appear 
to contribute to the 
access problems 
experienced by 
Medicaid patients. 
Web Exclusive ~ 
A more detailed O~U~[. 
analysis on this 
topic can be found in 
Research Report No.5, 
"Affording Prescription 
Drugs-Not Just a Problem 
for the Elderly;' available 
online at www.hschange.org. 
Figure 1 
Percent Not Obtaining Prescription Drug Due to Cost 
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• Difference from elderly with Medicare is statistically significant at p<.OS level. 
Note: The categories of employer coverage, Medicaid roverage and the uninsured include adults ages 18-64. 
Sou,.ce: Commumty Tracking Study Houselwld Survey, 2000-01 
Medicaid beneficiaries also tend to be in 
poorer health. More than half of non elderly 
adult beneficiaries are living with at least one 
chronic condition, such as diabetes, heart 
disease or depression, and more than one 
in four has two or more such conditions. 
In contrast, fewer than one-third of people 
with employer-sponsored coverage have a 
chronic condition, and only 10 percent have 
two or more conditions. 
Cost barriers are greater for people living 
with chronic conditions across all categories 
of insurance coverage (see Table 2). Especially 
striking is the high proportion of Medicaid 
beneficiaries and uninsured people with 
chronic health conditions who report being 
unable to afford prescription drugs. Perhaps 
most troubling, more than 40 percent of 
Medicaid patients with two or more chronic 
conditions reported not obtaining prescrip-
tion medications because of cost. 
Thus, low incomes and high prevalence 
of health problems put adult Medicaid bene-
ficiaries at high risk for experiencing prob-
lems in affording prescription medications. 
The study shows that these characteristics 
largely explain the wide gap between 
Medicaid and privately insured persons 
when it comes to affording prescription 
medications. But why has Medicaid-which 
was designed to narrow this gap-failed in 
this one critical aspect of care? 
Cost Containment Linked to 
Access Gaps 
State efforts to control Medicaid prescription 
drug spending appear to contribute to the 
access problems experienced by Medicaid 
patients. In the past few years, many states 
have implemented a variety of methods to 
control escalating Medicaid prescription 
drug spending. These methods attempt to 
control spending by influencing physicians' 
prescribing patterns and patients' drug use. 
Although methods vary from state to 
state, the most common include imposing 
nominal copayments, setting dispensing lim-
its that restrict the number of prescriptions, 
mandating substitution of generic drugs for 
brand-name drugs, requiring prior autho-
rization for certain drugs and issuing step-
therapy protocols that require physicians to 
Table 1 
Health and Income Characteristics by Insurance Type (ages 18-64) 
EMPLOYER-
MEDICAID/OrHER SPONSORED 
STATE CoVERAGE UNINSURED COVERAGE 
PERCENT WITH INCOMFS 
BELOW POVERTY 50% 26% 3% 
PERCENT WITH INCOMFS 
BElWEEN 100% AND 
200% OF POVElITY 25 30 11 
PERCENT WITH 1 CHRONIC 
CONDITION* 23 14 20 
PERCENT WITH 2 OR MORE 
CHRONIC CONDITIONS* 29 6 10 
" Conditions asked about in the su~y include diabetes, arthritis, asthma, chronic obstructive pulmonary disease, hype.rtension, 
coronary heart disease, cancer, benign prostate disease, depression and other serious medicaJ problems that limit usual activities. 
Note: Estimates reflect the percentage who responded "yes" to the following question: "During the past 12 months, was there 
any time you needed prescription medicines bu t didn't get them because you couJdn't afford it?" 
Source: ('.,ommllnily Tracking Study Household SlIrvey, 2000-01 
Table 2 
Percent Not Obtaining Prescription Drugs Due to Cost, by Insurance 
Coverage and Chronic Condition Status for Nonelderly Adults (ages 18-64) 
2 OR MORE 
No CHRONIC 1 CHRONIC CHRONIC 
CONDITIONS CoNDITION * CoNDITIONS* 
ALL PERSONS AGES 18-64 10% 17%** 25%** 
EMPLOYER-SPONSORED 
CoVERAGE 6 11** 15** 
MEDICAID AND OTHER 
STATE COVERAGE 16 26** 41** 
UNINSURED 23 48** 61** 
" Conditions asked about in the su~y indude diabetes, arthritis, asthma, chronic obstructive pulmonary disease, hypertension, 
coronary heart disease, cancer, benign prostate disease, depression and other serious medicaJ problems that limit usual activities. 
** Difference from persons with no chronic conditions is statistically significant at p< .05 level. 
Note: Estimates reflect the percentage who responded "yes" to the following question: "During the past 12 months, was there 
any time you needed prescription medicines but didn't get them because you couJdn't afford it?" 
Source: Commllnity Tracking Study HOllsehold Survey, 2()()()-Ol 
try lower-cost drugs before prescribing 
more costlyalternatives.3 
Individually, these cost controls do not 
appear to significantly affect beneficiaries' 
access to prescription drugs. Most states, 
however, have implemented more than 
one cost-control measure, and the study 
shows that when multiple cost-control 
measures are implemented, beneficiary 
access to prescription drugs is affected to a 
much greater extent (even after controlling 
for beneficiary characteristics and other 
community, state and regional factors). 
For example, beneficiaries in states that 
have implemented four or five cost-control 
measures were about twice as likely to 
o 
report cost barriers as those living in states 
with either one or no cost-control policies 
(see Figure 2). 
States that implement multiple cost-
control methods may be much more 
aggressive in trying to control Medicaid 
prescription drug spending. Not only 
would the cumulative effects of imple-
menting these policies curtail access to a 
greater degree than any single method, but 
the individual methods themselves also 
may be more stringent (e.g., higher copay-
ments, stricter dispensing limits) in states 
that are trying more aggressively to control 
spending. While greater Medicaid savings 
may be realized, an unintended conse-
quence of aggressive cost-control policies 
might be a reduction in beneficiary access 
to needed prescription drugs. 
Policy Implications 
While the recent policy debate has focused 
on expanding prescription drug coverage 
for senior citizens enrolled in Medicare, 
the HSC study suggests that policy makers 
should not ignore the difficulties many 
non elderly patients face in affording drugs, 
especially those who are uninsured or 
enrolled in Medicaid. 
The importance of prescription drugs 
in medical care is growing as both the 
number of people using prescription drugs 
and the number of prescriptions per user 
are increasing.4 Expenditures for prescrip-
tion drugs now account for about 11 per-
cent of personal health care expenses, up 
from about 6 percent in 1988.5 The impor-
tance and cost of prescription drugs in 
medical care are likely to increase in the 
future with the development of new drug 
products, including those from the still-
nascent biotechnology field. As drug prod-
ucts increase in both importance and cost, 
policy makers will be confronted with the 
challenge of making medications afford-
able and accessible to all Americans. 
Many states currently are experiencing 
Medicaid budget shortfalls, and state offi-
cials often point to rising Medicaid pre-
scription drug spending as a major cause. 
If these pressures continue or worsen, states 
may become even more aggressive in their 
efforts to control prescription drug expen-
·; .. I~ .. ' . . "' ." ,. ' . . " I / 
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Data Source 
This Issue Brief presents findings 
from the 2000-01 Community 
Tracking Study Household 
Survey, a nationally representa-
tive telephone survey of the 
civilian, noninstitutionalized 
population, supplemented by in-
person interviews of households 
without telephones to ensure 
proper representation. The survey 
contains observations on a total 
of about 60,000 persons. The 
sample for this study is based 
on 39,000 adults ages 18-64, 
including about 1,800 who are 
in Medicaid or state coverage. 
The response rate for the survey 
was around 60 percent. 
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Figure 2 
Summary of Effects of State Medicaid Cost-Control Methods on Beneficiaries' 
Acc 55 to Prescription Drugs· 
STATE HAs IMPLEMENTED 
o OR 1 METHOD 
STATE HAs IMPLEMENTED 
2 OR 3 METHODS 
STATE HAs IMPLEMENTED 
4 OR 5 METHODS 
o 
15% 
10 
25% 
33%** 
20 30 40 
PERCENT NOT GETTING 
PRESCRIPTION DRUG DUE TO COST*** 
* These methods include copayments, limits on the number of prescriptions, mandatory substitution of generics for brand-name 
drugs, preauthorization requirements and step-therapy requirements. 
U Difference from persons in states that have implemented 0 or 1 requirement is statistically significant at p<.OS. 
u* Estimates reflected regression-adjusted means that control for beneficiary characteristics and other community; state and regional 
factors. 
Note: Sample includes persons ages 18-64 enrolled in Medicaid or state coverage programs. 
Source: Community Tracking Study Household Survey, 2000-01 
ditures, further restricting beneficiary access. 
White some may view these cost-control 
methods as consistent with those used 
by many private insurers, public officials 
should keep in mind that the impact of 
these methods on Medicaid beneficiaries 
is likely to be greater given their higher 
need and lower incomes . • 
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1 THE COURT: Good afternoon. Be seated, 
2 please. 
3 In 2000 the Michigan Supreme Court, as we all 
4 know, decided the case of Blank ve~sus Michigan 
5 Department of Corrections, 462 Michigan 103. In that 
6 case the Department of Corrections r.ad promulgated a set 
7 of rules without the approval of what was then known as 
8 the joint committee on administrative rules, a:body 
9 appointed by both houses of the legislature consisting 
10 of members of the legislature. 
11 The legislature had enacted in 1977 a statute, 
12 Public Act 108, which required the approval of that 
13 joint committee on administrative rules bafore any 
14 executive agency could promulgate rules which 't'lould have 
15 the force and effect of law. 
16 A three-member plurality of the Michigan 
17 Supreme Court was joined by a fourth me~be=, which thus 
18 constituted a majority of the Supreme Court in holding 
19 that the legislative veto over rules proposed by an 
20 executive agency is inherently a legislative function 
21 and is thus subject to the enactment and presencment 
22 clauses of our state constitution, and ttis is true 
23 whether the veto is exercised b~ the entire legislat~re 
24 or something less thar. the entire legi91at~re, suet as, 
25 in tha~ case, a joi~c cc~mittee. 
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1 The Supreme Court further held that the 
2 statute in question delegated to that joint committee 
3 authority to perform what the Supreme Court recognized 
4 as essentially legislative acts and that the essence of 
5 this was the committee's ability to, quote, exert a 
6 policy-making effect equivalent to amending or repealing 
7 existing legislation, close quote, and, quote, 
8 therefore, such actions are subject to the ena~tment and 
9 presentment requirements of our 1963 constitution, close 
10 quote. I'm quoting there from page 117, footnote eight, 
11 and page 119 of the Blank decision. 
12 Turning to the case before the Court today, 
13 section 2204(1) req~i~es the Department of Comnunity 
14 Health to submit proposed changes in its so-called 
lS pharmacies' policies for non-HMO Medicaid re=ipients and 
16 certain others, to the chairs of the relevant senate and 
17 house appropriations sub-committees. There's nothing 
19 unconstitutional about the requirement of submitting 
19 that information. Eut subsection three gives those 
20 chairs 30 days to veto any such changes in these 
21 policies, and if those chairs do veto those policies, 
22 those policies may r.o lo~ger be executed. 
23 This violates the Mic~igan constitution in 
24 exactly the sa~e man~e~ and for exactly the saxe reason 
2S as 1977 Public Act lCB was declared to do so i~ the 
30th JUDICIAL CIRCUIT CCURT 
333 South Capito: Avenue Suite C Lansing, MI 49933 
76 
1 Ela~k case. 
2 The Defendant argues that even if this 
3 requirement is unconstitutional, it is moot because the 
4 veto was r.ot exercised within 30 days and cannot now be 
5 exercised. But the fact that the chairs of the 
6 committees did not disapprove of these changes does not 
7 make the issue moot, in my opinion. The power of the 
8 chairs, and in certain circumstances the 8enat~ and 
9 house leaders, to disapprove these changes must 
10 necessarily have been taken into account in designing 
11 the changes. It is impossible to find out all of the 
12 formal and informal communications which may have taken 
13 place between these legislators and/or their staffs en 
14 the one hand, and the people in the department who were 
15 working on these policies on the other ha~d. But to 
16 presume that there were no such communications defies 
17 common sense. In other words, once the chairs had the 
18 veto, it is clear that the wishes of the chairs, either 
19 expressly communicated or inferred, would have to be 
20 taken into account in designing the changes. This to me 
21 taints the entire plan and makes it an unconstitutior.al 
22 exercise. 
23 In addition, I agree ·with the Plaintiffs that 
24 the Defendant has failed to cite a:lY substantive 
25 9~atutory a~~hority fo~ t~e recovery of so-called 
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1 supplemental rebates. No where has the Defendant ~it~d 
2 or quoted any federal or state statute which authorizes 
3 a state agency to require a rebate in additio~ to or 
4 beyond that expressly authorized in section 
5 1396R(C) (1) (c) (i) of the Social Security Act. To me 
6 that section of the Social Security Act merely 
7 recognizes that states may, if properly authorized by 
8 their legislatures, create their own programs ~- not 
9 federal programs -- which result in lower prescription 
10 drug prices. However, the section of the federal act 
11 which has been cited by the Defendant does not and 
12 cannot autho~ize states to do so. This can only be done 
13 by the respective state legislatures throug~ duly 
14 enacced state statutes. So the department does not have 
15 the authority to require supplemental rebates. 
16 I agree with the Defendant that the so-called 
17 veto provisions of section 2204(3) would be severable 
18 under the tests laid out in MeL 8.5. That is to say, 
19 although it is invalid, the rest of the stat~te is not 
20 permeated with it. However, as I have said earlier, it 
21 is my view that once this veto was granted, it must 
-
22 necessarily have res~lted in the executive depart~ent 
23 taking into account the actual ~r presumed views of the 
24 c~airs of tr.e respective s~b-committees, and ttis tai~ts 
2S the e~tire exercise. 
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1 Now, as to the granting of an injunction. I 
2 have said this morning that time constraints have not 
3 allowed the Court to hear the separate mot~on of the 
4 Intervening Plaintiffs for preliminary injunction. 
5 However, I believe that I may take judicial ~otice of at 
6 least some of the Intervening Plaintiffs' r.eeds and 
7 characteristics. 
8 It is indisputable that disadvantage4 persons 
9 who are in need of continuing medical services which 
10 involve prescription drugs will be affected by these 
11 programs. The system of telephone appeals to a 
12 technician and then to a pharmacist and then to a 
13 physician, only during business hours, will undoubtedly 
14 result in delays in the dispensing of the medications 
15 which physicians judge to be medically ~ecessar/, and 
16 this is putting the best face on it as described by 
17 counsel for the Defe~dants. To me this constitutes 
18 irreparable harm to those patients who w~uld be so 
19 affected. 
20 I have not ruled that preapproval per se is 
21 unlawful or unconstitutional. Indeed, it is expressly 
22 authorized by the appro?riations act. r.owever, I may 
23 take into accot:.nt realistic expe'ctations as to t~e 
24 effects t~e p~eapprcval precess will ~ave i~ dete=rnining 
25 whether the uncons=itutional provisior.s ~ake it 
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1 necessary under the applicable standards for me to grant 
2 the injunction. 
3 The patie~t9 will be dramatically and 
4 immediately affected in their personal health. The ha~m 
5 to the state will be monetary. Thus, the balance of 
6 prospective harms favors the Intervening ~laintiffs. In 
7 saying this, I do not in any sense intend to make light 
8 of what I believe we all know is a very seriou~ fiscal 
9 and budgetary situation for the state governmen~, but 
10 under my view of the constitutional and statutory 
11 issues, I believe that the Plaintiffs are much more 
12 harmed in this case, and that is to say, the Intervening 
13 Pla~ntiff9, than the Defendant, and they are most likely 
14 to prevail for the reasons I have already stated. Thus, 
15 under the standards which I must follow, the injunctio~ 
16 must issue, and I will issue it. 
17 I will ask that the attorneys for the 
18 Plaintiffs get together and draft an appropriate 
19 injunction with approval as to form by the Defendants, 
20 not to be unreasonably withheld. 
21 MS. MARSDEN: Your Ho~or, at this time we 
22 would like to make an oral motio~ for a stay of ~he 
23 preliminary ~nj~ction pendir.g "emergency appeal to the 
24 Cc~rt of Appeals. 
25 THE COURT: Response? 
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1 MR. MARSAC: We oppose that, Your Honor. I 
2 think what the State is asking for is that they be 
3 allowed to proceed with what the Court has already 
4 determined to be an unconstitutional format. I think to 
5 stay the proceedings at this point -- to stay the 
6 issuance of the injunction would allow them to proceed 
7 and engage in conduct that would render irreparable 
8 injury to the parties, and I think it would be_totally 
9 inappropriate under the circumstances. It would 
10 undermined the Court's order. 
11 MR. CODY: We would join in that, Your Eonor. 
12 THE COURT: You may seek a stay from the Court 
13 of Appeals along with your emergency appeal. 
14 MS. MARSDEN: Your Honor, I have prepared a 
15 proposed order denying stay. May r present it for your 
16 signature? 
17 THE COURT: Yes. Also seek approva2 as to 
18 form. 
MS. MARSDEN: Yes. 
20 THE COURT: r want you also all to get 
21 together this afternoon and try to get an injunction 
22 batted out that I can sigr. ft so that is not a barrier 
23 to the State's ability to pursue this appeal. 
24 ~S. MARSDEN: Thank you, Your Honor. 
25 THE COURT: &~d if that p~oves i~poss:~le, r 
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1 may have to consider an emergency motion tomorrow 
2 afternoon. In other words, although I obviously feel 
3 that I've made the correct decision, I don't want to do 
4 anything to hobble the State's ability to see if the 
5 Court of Appeals, and ultimately the Supreme Court, may 
6 disagree. 
7 MS. MARSDEN: Your Honor 
8 THE COURT: No dispute as to form on_this 
9 order of denying motion for stay? 
10 MR. MARSAC: I don't believe so, Your Honor. 
11 THE COURT: All right. 
12 MR. CODY: None, Your Honor. 
13 MS. MARSDEN: Your Honor, if I might suggest 
14 now, and this, perhaps, would simplify matters, I would 
15 not be opposed to an order saying that the injunction is 
16 issued for the reasons stated by the Court, and then we 
17 don't have a problem agreeing to the verbiage, and we'll 
18 get a copy of the transcript. I think that's the 
19 easiest way. 
20 MR. ~~SAC: Your Honor, we have an o=der that 
21 we had attached to our motion. Per~aps counsel ought ~o 
22 take a quick review of that and advise the Court whether 
23 it's acceptable. 
24 THE COURT: You folks take a look at that anc 
25 see if you can ag=ee o~ somethi~g. II1l be ~~ my 
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1 chambers in the foreseeable future. If you cannot 
2 agree, then r as I say, tomorrow you can seek emergency 
3 relief some time late in the morning, early afternoon. 
4 I will give you back this order denying the 
5 motion to stay, which I've signed. I think I have the 
6 court file in my office. No, here it is. The clerks 
7 downstairs on the first floor will be happy to take 
8 this. 
--
9 MS. MARSDEN: Thank you very much. 
10 THE COURT: Anything else? 
11 MR. MARSAC: That's all. We'll work on the 
12 order. 
13 THE COURT: Thank you. 
14 (Whereupon hearing concluded at 3:16 p.m.) 
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CURRENT 2003 BUDGET LANGUAGE 
Page 49 
14 Sec 1627. (1) The department shall use provisions specified under 
Section 1927 of title XIX of the social security act, 42 U.S.C. 1396r-8, to secure 
quarterly rebates from pharnlaceutical manufacturers for drugs dispensed to 
participants in state-funded programs. 
19 2) for products distributed by pharmaceutical manufacturers not providing 
quarterly rebates as listed in subsection (1), the department may require 
preauthorization for prescriptions dispensed to participants in state-funded 
programs. 
AMEND SEC. 1627 OF THE 2003 BUDGET BILL TO READ AS FOLLOWS: 
Sec. 16287. (1) The department may negotiate with pharmaceutical 
manufacturers to obtain the same level of quarterly rebates as specified 
under Section 1927 of title XIX of the social security act, 42 U.S.C. 1396r-8 
for drugs dispensed to Medicaid recipients enrolled in managed care plans 
and to participants in the following state-funded programs: Elderly 
P,rescription Insurance Coverage Program (EPIC), MI Family, Children 
With Special Health Care Needs, Wayne County Pluscare and MI 
Department of Corrections. 
2) Products of pharmaceutical manufacturers that provide quarterly 
rebates pursuant to subsection (1), shall be made available in the Medicaid 
program and to the participants in the programs listed in subsection (1) 
without prior authorization or other restrictions. 
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SENATE BILL No. 1101 -
February 13, 2002, Introduced by Senators Gougeon, Schwarz, Johnson and Smith and 
referred to the Committee on Appropriations. 
EXECUTIVE BUDGET BILL 
A bill to make appropriations for the department of community 
health and certain state purposes related to aging, mental health, 
public health, and medical services for the fiscal year ending 
September 30, 2003; to provide for the expenditure of such 
appropriations; to create funds; to provide for reports; to 
prescribe the powers and duties of certain local and state 
agencies and departments; and to provide for disposition of fees 
and other income received by the various- state agencies. 
THE PEOPLE OF THE STATE OF MICHIGAN ENACT: 
PART 1 
LINE-ITEM APPROPRIATIONS 
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1 (2) When carved-out of the capitation rate for managed care 
2 recipients, the pharmaceutical dispensing fee shall be $3.77 or 
3 the pharmacy's usual or customary cash charge or the usual charge 
4 allowed by the recipients's medicaid HMO, whichever is less. 
5 (3) The department shall require a prescription copayment for 
6 medicaid recipients except as prohibited by federal or state law 
7 or regulation. 
8 Sec. 1624. An additional $20,000,000.00 in tobacco settlement 
9 funds are hereby appropriated to the elder prescription insurance 
10 coverage program if the state budget director certifies that the 
11 federal funds appropriated to that program are unavailable and 
12 that sufficient tobacco settlement revenue is available to finance 
13 this appropriation. 
14 Sec. 1627. (1) The department shall use provisions specified 
15 under section 1927 of title XIX of the social security act, 42 
16 u.s.c. 1396r-8, to secure quarterly rebates from pharmaceutical 
17 manufacturers for outpatient drugs dispensed to participants in 
18 state-funded programs. 
19 2) For products distributed by pharmaceutical manufacturers 
20 not providing quarterly rebates as listed in subsection (1), the 
21 department may require preauthorization for prescriptions 
22 dispensed to participants in state-funded programs. 
23 Sec. 1631. The department shall require copayments on dental, 
24 podiatric, chiropractic, vision, and hearing aid services provided 
25 to Medicaid recipients, except as prohibited by federal or state 
26 law or regulation. 
27 Sec. 1641. An institutional provider that is required to 
28 submit a cost report under the medical services program shall 
06627'02 
SB 1101, As Passed Senate, March 20, 2002 
Senate Bill No. 1101 75 
1 Medicaid, unless subsequent consultation with the prescribing physician 
2 indicates otherwise. 
3 Sec. 1624. (1) An additional $20,000,000.00 from the tobacco set-
4 tlement trust fund is appropriated to the elder prescription insurance 
5 coverage program for fiscal year 2002-2003 if the state budget director 
6 certifies that the federal funds appropriated to that program are 
7 unavailable and that sufficient tobacco settlement revenue is available 
8 to finance this appropriation. As used in this section, "tobacco settle-
9 ment revenue" and "tobacco settlement trust fund" mean those terms as 
10 defined in section 2 of the Michigan trust fund act, 2000 P~489, 
11 MCL 12.252. 
12 (2) None of the tobacco settlement or other state restricted revenue 
13 appropriated by the department to the EPIC program in fiscal year 
14 2001-2002 shall lapse. 
15 (3) The department shall place any funds that would have lapsed in a 
16 reserve account for the sole purpose of providing revenue to fund the 
17 EPIC program during fiscal year 2002-2003, in t~e event the proposed fed-
18 eral revenue to enhance EPIC program funding is not available. 
19 (4) If the proposed federal funds become available, the reserved 
20 tobacco settlement funds may either be lapsed to the tobacco settlement 
21 trust fund or the Medicaid trust fund. 
22 Sec. 1627. (1) The department may negotiate with pharmaceutical 
23 manufacturers to obtain the same level of quarterly rebates described in 
24 section 1927 of title XIX, 42 U.S.C. 1396r-8, for drugs dispensed to 
25 Medicaid recipients enrolled in managed care plans and to participants in 
26 the eligible programs. 
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1 (2) The program described in subsection (1) shall meet all of the 
2 .following: 
3 (a) The rebates shall be payable for drugs dispensed to Medicaid 
4 recipients enrolled in managed care plans only upon written confirmation 
5 by the United States secretary of health and human services that the 
6 rebates are not included in computing the manufacturer's best price as 
7 defined in section 1927(c) (1) (C) of title XIX, 42 U.S.C. 1396r-8. 
8 (b) The rebates shall be payable for drugs dispensed to participants 
9 in each of the eligible programs only upon written confirmation by the 
10 United States secretary of health and human services that the rebates 
11 paid for each eligible program are not included in computing the 
12 manufacturer's best price as defined in section 1927 (c) (1) (C) of title 
13 XIX, 42 U.S.C. 1396r-8. 
14 (c) The per unit rebate amount reported by each participating phar-
15 maceutical manufacturer to the state for purposes of this section shall 
16 be maintained in confidence and used only for purposes of administering 
17 this program, and shall not be disclosed in a f~rm that reveals directly 
18 or indirectly the rebate amount for a specific drug or rebates payable by 
19 a pharmaceutical manufacturer. 
20 (3) Pharmaceutical manufacturers that provide quarterly rebates pur-
21 suant to subsection (1) for all of their products dispensed for all par-
22 ticipants in all eligible programs shall have all of their products made 
23 available without prior authorization or other restrictions in the 
24 Medicaid program, except for those drugs for which the department 
25 required prior authorization during fiscal year 2000-2001 and except for 
26 those drugs dispensed to Medicaid recipients enrolled in health plans. 
S06627'02 (S-l) 
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1 (4) As used in this section, "eligible programs" means the following 
2 ~rograms funded by this state: the elder prescription insurance coverage 
3 program, MIFamily or its predecessor programs, children's special health 
4 care services, Wayne County pluscare, and any medical care program oper-
5 ated by the department of corrections or another state facility. 
6 Sec. 1628. It is the intent of the legislature that if the savings 
7 for Medicaid pharmacy rebates .exceed the amount budgeted in this act, the 
8 savings shall first be used to offset any increase in pharmacy costs 
9 above that budgeted in this act and then to support and expand coverage 
10 under the EPIC program. 
11 Sec. 1630. Medicaid adult dental services, podiatric services, and 
12 chiropractic services shall continue at not less than the level in effect 
13 on October 1, 1996, except that reasonable utilization limitations may be 
14 adopted in order to prevent excess utilization. The department shall not 
15 impose utilization restrictions on chiropractic services unless a recipi-
16 ent has exceeded 18 office visits within 1 year. 
17 Sec. 1631. The department shall require copayrnents on dental, podi-
18 atric, chiropractic, vision, and hearing aid services provided to 
19 Medicaid recipients, except as prohibited by federal or state law or 
20 regulation. 
21 Sec. 1633. From the funds appropriated in part 1 for auxiliary med-
22 ical services, the department shall expand the healthy kids dental pro-
23 gram statewide if funds become available specifically for expansion of 
24 the program. 
25 Sec. 1634. (1) From the funds appropriated in part 1 for ambulance 
26 services, the department shall continue the 5% increase in payment rates 
S06627'02 (S-l) 
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